<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia - Welsch, P - 2018 | Cochrane Library</title> <meta content="Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia - Welsch, P - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010292.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia - Welsch, P - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010292.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010292.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia" name="citation_title"/> <meta content="Patrick Welsch" name="citation_author"/> <meta content="Health Care Center for Pain Medicine and Mental Health" name="citation_author_institution"/> <meta content="Nurcan Üçeyler" name="citation_author"/> <meta content="University of Würzburg" name="citation_author_institution"/> <meta content="Petra Klose" name="citation_author"/> <meta content="University of Duisburg-Essen" name="citation_author_institution"/> <meta content="Brian Walitt" name="citation_author"/> <meta content="National Institutes of Health" name="citation_author_institution"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="whaeuser@klinikum-saarbruecken.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD010292.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010292.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010292.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010292.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic Uptake Inhibitors [*therapeutic use]; Carnitine [therapeutic use]; Cyclopropanes [*therapeutic use]; Desvenlafaxine Succinate [*therapeutic use]; Duloxetine Hydrochloride [*therapeutic use]; Fibromyalgia [*drug therapy]; Milnacipran; Norepinephrine [*metabolism]; Pregabalin [therapeutic use]; Quality of Life; Selective Serotonin Reuptake Inhibitors [*therapeutic use]; Syndrome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010292.pub2&amp;doi=10.1002/14651858.CD010292.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010292\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010292\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","pt","pl","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010292.pub2",title:"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia",firstPublishedDate:"Feb 28, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010292.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010292.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010292.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010292.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010292.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010292.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010292.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010292.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010292.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010292.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9166 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010292.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0159"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-sec-0153"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/appendices#CD010292-sec-0171"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/table_n/CD010292StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/table_n/CD010292StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#CD010292-cr-0004">Patrick Welsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#CD010292-cr-0005">Nurcan Üçeyler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#CD010292-cr-0006">Petra Klose</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#CD010292-cr-0007">Brian Walitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information#CD010292-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information/en#CD010292-sec-0181">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010292.pub2">https://doi.org/10.1002/14651858.CD010292.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010292-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010292-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010292-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010292-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010292-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010292-abs-0001" lang="en"> <section id="CD010292-sec-0001"> <h3 class="title" id="CD010292-sec-0001">Background</h3> <p>Fibromyalgia is a clinically defined chronic condition of unknown etiology characterized by chronic widespread pain that often co‐exists with sleep disturbances, cognitive dysfunction and fatigue. People with fibromyalgia often report high disability levels and poor quality of life. Drug therapy, for example, with serotonin and noradrenaline reuptake inhibitors (SNRIs), focuses on reducing key symptoms and improving quality of life. This review updates and extends the 2013 version of this systematic review. </p> </section> <section id="CD010292-sec-0002"> <h3 class="title" id="CD010292-sec-0002">Objectives</h3> <p>To assess the efficacy, tolerability and safety of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults. </p> </section> <section id="CD010292-sec-0003"> <h3 class="title" id="CD010292-sec-0003">Search methods</h3> <p>For this update we searched CENTRAL, MEDLINE, Embase, the US National Institutes of Health and the World Health Organization (WHO) International Clinical Trials Registry Platform for published and ongoing trials and examined the reference lists of reviewed articles, to 8 August 2017. </p> </section> <section id="CD010292-sec-0004"> <h3 class="title" id="CD010292-sec-0004">Selection criteria</h3> <p>We selected randomized, controlled trials of any formulation of SNRIs against placebo or any other active treatment of fibromyalgia in adults. </p> </section> <section id="CD010292-sec-0005"> <h3 class="title" id="CD010292-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted data, examined study quality, and assessed risk of bias. For efficacy, we calculated the number needed to treat for an additional beneficial outcome (NNTB) for pain relief of 50% or greater and of 30% or greater, patient's global impression to be much or very much improved, dropout rates due to lack of efficacy, and the standardized mean differences (SMD) for fatigue, sleep problems, health‐related quality of life, mean pain intensity, depression, anxiety, disability, sexual function, cognitive disturbances and tenderness. For tolerability we calculated number needed to treat for an additional harmful outcome (NNTH) for withdrawals due to adverse events and for nausea, insomnia and somnolence as specific adverse events. For safety we calculated NNTH for serious adverse events. We undertook meta‐analysis using a random‐effects model. We assessed the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD010292-sec-0006"> <h3 class="title" id="CD010292-sec-0006">Main results</h3> <p>We added eight new studies with 1979 participants for a total of 18 included studies with 7903 participants. Seven studies investigated duloxetine and nine studies investigated milnacipran against placebo. One study compared desvenlafaxine with placebo and pregabalin. One study compared duloxetine with L‐carnitine. The majority of studies were at unclear or high risk of bias in three to five domains. </p> <p>The quality of evidence of all comparisons of desvenlafaxine, duloxetine and milnacipran versus placebo in studies with a parallel design was low due to concerns about publication bias and indirectness, and very low for serious adverse events due to concerns about publication bias, imprecision and indirectness. The quality of evidence of all comparisons of duloxetine and desvenlafaxine with other active drugs was very low due to concerns about publication bias, imprecision and indirectness. </p> <p>Duloxetine and milnacipran had no clinically relevant benefit over placebo for pain relief of 50% or greater: 1274 of 4104 (31%) on duloxetine and milnacipran reported pain relief of 50% or greater compared to 591 of 2814 (21%) participants on placebo (risk difference (RD) 0.09, 95% confidence interval (CI) 0.07 to 0.11; NNTB 11, 95% CI 9 to 14). Duloxetine and milnacipran had a clinically relevant benefit over placebo in patient's global impression to be much or very much improved: 888 of 1710 (52%) on duloxetine and milnacipran (RD 0.19, 95% CI 0.12 to 0.26; NNTB 5, 95% CI 4 to 8) reported to be much or very much improved compared to 354 of 1208 (29%) of participants on placebo. Duloxetine and milnacipran had a clinically relevant benefit compared to placebo for pain relief of 30% or greater. RD was 0.10; 95% CI 0.08 to 0.12; NNTB 10, 95% CI 8 to 12. Duloxetine and milnacipran had no clinically relevant benefit for fatigue (SMD ‐0.13, 95% CI ‐0.18 to ‐0.08; NNTB 18, 95% CI 12 to 29), compared to placebo. There were no differences between either duloxetine or milnacipran and placebo in reducing sleep problems (SMD ‐0.07; 95 % CI ‐0.15 to 0.01). Duloxetine and milnacipran had no clinically relevant benefit compared to placebo in improving health‐related quality of life (SMD ‐0.20, 95% CI ‐0.25 to ‐0.15; NNTB 11, 95% CI 8 to 14). </p> <p>There were 794 of 4166 (19%) participants on SNRIs who dropped out due to adverse events compared to 292 of 2863 (10%) of participants on placebo (RD 0.07, 95% CI 0.04 to 0.10; NNTH 14, 95% CI 10 to 25). There was no difference in serious adverse events between either duloxetine, milnacipran or desvenlafaxine and placebo (RD ‐0.00, 95% CI ‐0.01 to 0.00). </p> <p>There was no difference between desvenlafaxine and placebo in efficacy, tolerability and safety in one small trial. </p> <p>There was no difference between duloxetine and desvenlafaxine in efficacy, tolerability and safety in two trials with active comparators (L‐carnitine, pregabalin). </p> </section> <section id="CD010292-sec-0007"> <h3 class="title" id="CD010292-sec-0007">Authors' conclusions</h3> <p>The update did not change the major findings of the previous review. Based on low‐ to very low‐quality evidence, the SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in the frequency of pain relief of 50% or greater, but for patient's global impression to be much or very much improved and in the frequency of pain relief of 30% or greater there was a clinically relevant benefit. The SNRIs duloxetine and milnacipran provided no clinically relevant benefit over placebo in improving health‐related quality of life and in reducing fatigue. Duloxetine and milnacipran did not significantly differ from placebo in reducing sleep problems. The dropout rates due to adverse events were higher for duloxetine and milnacipran than for placebo. On average, the potential benefits of duloxetine and milnacipran in fibromyalgia were outweighed by their potential harms. However, a minority of people with fibromyalgia might experience substantial symptom relief without clinically relevant adverse events with duloxetine or milnacipran. </p> <p>We did not find placebo‐controlled studies with other SNRIs than desvenlafaxine, duloxetine and milnacipran. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010292-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010292-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010292-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010292-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010292-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010292-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010292-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010292-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010292-abs-0002" lang="en"> <h3>Serotonin and noradrenaline reuptake inhibitors for fibromyalgia</h3> <p><b>Bottom line</b> </p> <p>Duloxetine and milnacipran may reduce pain in people with fibromyalgia. However, some of these people may also experience side effects, such as nausea (feeling sick) and drowsiness. A minority of people with fibromyalgia experience symptom relief without side effects from duloxetine and milnacipran. </p> <p><b>Background</b> </p> <p>People with fibromyalgia often have chronic (longer than three months) widespread pain, as well as problems with sleep, thinking and exhaustion. They often report poor health‐related quality of life. There is no cure for fibromyalgia at present, so the treatments aim to relieve the symptoms and to improve health‐related quality of life. </p> <p>Serotonin and noradrenaline are chemicals which are produced by the human body, involved in the regulation of pain, sleep and mood. Low concentrations of serotonin have been reported in people with fibromyalgia. Serotonin and noradrenaline reuptake inhibitors (SNRIs) are a class of antidepressants that increase the concentration of serotonin and noradrenaline in the brain. </p> <p><b>Study characteristics</b> </p> <p>In August 2017, we updated our searches for clinical trials in which SNRIs were used to treat symptoms of fibromyalgia in adults. We found eight new studies since the previous version of the review. In total, we found 18 studies with 7903 participants. The studies were four to 27 weeks long and compared the SNRIs desvenlafaxine, duloxetine and milnacipran against a fake medication (placebo). We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low‐quality evidence means that we are very uncertain about the results. High‐quality evidence means that we are very confident in the results. </p> <p><b>Key results and quality of the evidence</b> </p> <p>Duloxetine and milnacipran were better than placebo in reducing pain by 50% or more and in improving global well‐being (low‐quality evidence). Duloxetine and milnacipran were better than placebo in improving health‐related quality of life and in reducing fatigue (low‐quality evidence). Duloxetine and milnacipran were not better than placebo in reducing sleep problems (low‐quality evidence). More people dropped out of the trial due to side effects with duloxetine and milnacipran than with placebo (low‐quality evidence). More people reported nausea and drowsiness with duloxetine and milnacipran than with placebo (low‐quality evidence). Duloxetine, milnacipran and placebo did not differ in the frequency of serious side effects experienced (very low‐quality evidence). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010292-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010292-sec-0159"></div> <h3 class="title" id="CD010292-sec-0160">Implications for practice</h3> <section id="CD010292-sec-0160"> <section id="CD010292-sec-0161"> <h5 class="title">For people with fibromyalgia</h5> <p>Only a minority of people may profit from treatment with the serotonin and noradrenaline reuptake inhibitors (SNRIs) duloxetine and milnacipran in terms of meaningful relief of fibromyalgia symptoms and a good tolerability of the drug. The majority of people will not experience substantial relief of fibromyalgia symptoms or will terminate the treatment because of adverse events, or both. There is no evidence for the efficacy of other SNRIs such as desvenlafaxine and venlafaxine. </p> </section> <section id="CD010292-sec-0162"> <h5 class="title">For physicians</h5> <p>If duloxetine or milnacipran are being considered for the treatment of fibromyalgia, a frank discussion between the physician and patient about the potential benefits and harms of both drugs is important. The contraindications (concomitant use of monoamine oxidase inhibitors, uncontrolled narrow‐angle glaucoma, substantial alcohol use or evidence of chronic liver damage) and warnings (suicidality, hepatotoxicity, serotonin syndrome, abnormal bleeding, discontinuation syndrome, elevated blood pressure, urinary hesitation and retention) are to be discussed (<a href="./references#CD010292-bbs2-0078" title="HäuserW , PetzkeF , SommerC . Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain2010;6:505-21.">Häuser 2010b</a>). Defining realistic goals of therapy (e.g. pain relief of 30% or more and/or improvement of daily functioning) by people with fibromyalgia and their physicians before starting drug treatment has been recommended (<a href="./references#CD010292-bbs2-0086" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , KoppI . Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain. Schmerz2015;29:8-34.">Häuser 2015b</a>). </p> <p>The recommended dosages are duloxetine 60 mg a day, and milnacipran 100 mg a day. A dose response has not been demonstrated. Higher doses are associated with more adverse events (<a href="./references#CD010292-bbs2-0060" title="CordingM , DerryS , PhillipsT , MooreRA , WiffenPJ . Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD008244]">Cording 2015</a>; <a href="./references#CD010292-bbs2-0078" title="HäuserW , PetzkeF , SommerC . Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain2010;6:505-21.">Häuser 2010b</a>). Treatment has only been continued in responders, that is to say in people who reached the predefined treatment goals with a reasonable tolerability of duloxetine or milnacipran (<a href="./references#CD010292-bbs2-0111" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , Kühn T et al. General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles. Schmerz2017;31:246-54.">Petzke 2017</a>). </p> <p>A class effect of SNRIs on fibromyalgia symptoms cannot be assumed. One study found no difference between four dosages of desvenlafaxine and placebo in mean pain intensity reduction (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). One study found no differences between venlafaxine and placebo in all outcomes of efficacy (<a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>). </p> <p>Treating fibromyalgia with drugs only, such as SNRIs alone, is discouraged since current best practices in fibromyalgia guidelines recommend using the combination of pharmacological therapy with aerobic exercise and psychological therapies (<a href="./references#CD010292-bbs2-0043" title="AblinJ , FitzcharlesMA , BuskilaD , ShirY , SommerC , HäuserW . Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence-based Complementary and Alternative Medicine: ECAM2013;2013:485272.">Ablin 2013</a>; <a href="./references#CD010292-bbs2-0096" title="MacfarlaneGJ , KronischC , AtzeniF , HäuserW , ChoyEH , Amris K et al. EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases2017;76:318-328.">MacFarlane 2017</a>; <a href="./references#CD010292-bbs2-0111" title="PetzkeF , BrückleW , EidmannU , HeldmannP , KöllnerV , Kühn T et al. General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles. Schmerz2017;31:246-54.">Petzke 2017</a>).This is especially true for symptoms where duloxetine and milnacipran are ineffective, but other therapies are effective, for example, aerobic exercise for fatigue (<a href="./references#CD010292-bbs2-0079" title="HäuserW , KloseP , LanghorstJ , MoradiB , SteinbachM , Schiltenwolf M et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research Therapy2010;12(3):R79.">Häuser 2010c</a>), and cognitive‐behavioral therapies for depression (<a href="./references#CD010292-bbs2-0051" title="BernardyK , KloseP , WelschP , HäuserW . Cognitive behavioural therapies for fibromyalgia syndrome. European Journal of Pain2017;22:in press. [DOI: 10.1002/14651858.CD009796.pub2]">Bernardy 2017</a>). </p> <p>Since relatively few participants achieve a worthwhile response with SNRIs, it is important to establish stopping rules, so that when someone does not respond within a specified time, they can be switched to an alternative treatment. This will reduce the number of participants exposed to adverse events in the absence of benefit. One study included in this review demonstrated that some people with fibromyalgia who do not respond to duloxetine might respond to milnacipran (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>). </p> </section> <section id="CD010292-sec-0163"> <h5 class="title">For policy‐makers</h5> <p>Since no single treatment is effective in a majority of individuals with fibromyalgia, this relatively small number who benefit may be considered worthwhile, particularly if appropriate switching or stopping rules are in place. </p> </section> <section id="CD010292-sec-0164"> <h5 class="title">For funders</h5> <p>Treatment with duloxetine and milnacipran for fibromyalgia may be considered worthwhile, particularly if switching and stopping rules are in place in case the predefined treatment goals are not reached or the drugs are not well tolerated, or both. It is important that the treatment is supervised by a physician experienced in the treatment with duloxetine and milnacipran. </p> </section> </section> <h3 class="title" id="CD010292-sec-0165">Implications for research</h3> <section id="CD010292-sec-0165"> <section id="CD010292-sec-0166"> <h5 class="title">General</h5> <p>Analysis of all studies investigating duloxetine and milnacipran in fibromyalgia at the level of individual participant data could provide important information, for example, whether or not a clinically important pain response delivers large functional and quality‐of‐life benefits. Moreover, a re‐analysis of the data using baseline observation carried forward, and responder analysis where discontinuation is classified as non‐response, would allow a determination of the true efficacy of duloxetine and milnacipran in fibromyalgia. All journals should follow the BMJ rule that reports of randomized trials will only be considered for publication if the authors commit to making the relevant anonymous participant‐level data available on reasonable request (<a href="./references#CD010292-bbs2-0052" title="BMJ. Research. www.bmj.com/about-bmj/resources-authors/article-types/research.">BMJ</a>). </p> <p>Studies in any continent and the inclusion of people with inflammatory rheumatic diseases, osteoarthritis and mental disorders (depressive and anxiety disorders, post‐traumatic stress disorder) are necessary to provide external validity of the study findings. </p> <p>A standardized psychiatric interview at study entry can stratify participants according to comorbid anxiety and depressive disorders. </p> <p>There is bias towards studies conducted in USA. To provide generalizability of study results, study populations equally recruited from every continent are necessary. </p> <p>It is necessary that the details of the assessment of adverse events (spontaneous reports, open questions, symptom questionnaires) are reported by the studies because the type and frequency of adverse events is influenced by the modes of assessment (<a href="./references#CD010292-bbs2-0081" title="HäuserW , BartramC , Bartram-WunnE , TölleT . Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clinical Journal of Pain2012;28:437-51.">Häuser 2012</a>). It is mandatory that adverse events should be reported using the International Conference on Harmonization guidelines, and coded within organ classes using the Medical Dictionary for Regulatory Activities (MedDRA) (<a href="./references#CD010292-bbs2-0088" title="International Council for Harmonisation. Medical Dictionary for Regulatory Activities Version 19.1. www.meddra.org/news-and-events/news/all-translations-meddra-version-191-are-now-available 20162016.">International Council for Harmonisation 2016</a>). It is desirable that regulatory agencies standardize the assessment strategies of adverse events in RCTs. </p> <p>It is important to control for potential effects of co‐interventions on outcomes.</p> </section> <section id="CD010292-sec-0167"> <h5 class="title">Measurement (endpoints)</h5> <p>It is important to use responder criteria for a clinically relevant improvement of sleep problems, fatigue, depression and physical function (disability) (<a href="./references#CD010292-bbs2-0047" title="ArnoldLM , WilliamsDA , HudsonJI , MartinSA , ClauwDJ , Crofford LJ et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism2012;64:885-94.">Arnold 2012b</a>). Homogeneous outcomes for studies with an EERW design need to be defined. </p> </section> <section id="CD010292-sec-0168"> <h5 class="title">Comparison between active treatments</h5> <p>It is important not only to compare with placebo but also with drugs with known efficacy, such as amitriptyline or pregabalin. In addition, more studies with defined subgroups (e.g. major depression, no adequate response to a specific drug treatment) are necessary. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010292-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010292-sec-0008"></div> <div class="table" id="CD010292-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fibromyalgia </p> <p><b>Settings:</b> study centers in North, Central and South America, Asia and Europe </p> <p><b>Intervention:</b> serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with intervention</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect</b> </p> <p><b>SMD or risk difference</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported pain relief of 50% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b> </p> <p><b>(282 to 344)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.09 (0.07 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6918 (15 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (95% CI 9 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression to be much or very much improved (PGIC)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b> </p> <p><b>(459 to 573)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.19 (0.12 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2918 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 5 (95% CI 4 to 8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported fatigue (20‐100 scale)</b> </p> <p>Higher scores indicate higher fatigue problem levels</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean fatigue<br/>score was 2.6 points<br/>lower (1.0 to<br/>5.0 points lower) based on a 20‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 69.4 (SD 12.3)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.18 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6168 (12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 18 (95% CI 12 to 29)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported sleep problems</b> </p> <p><b>(0‐100 scale)</b> </p> <p>Higher scores indicate higher sleep problem levels</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean sleep problems<br/>score was 1.2 points<br/>lower (0.2 higher to<br/>5.5 points lower) based on a 0‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 68.0 (23.8)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.07 (‐0.15 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4547 (8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported health‐related quality of life (0‐100 scale)</b> </p> <p>Higher scores indicate higher burden of disease (lower quality of life)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean health‐related quality of life problems score was 3.9 points lower (2.3 to<br/>5.3 points lower) based on a<br/>0‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 57.9 (SD<br/>14.1)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.20 (‐0.25 to ‐0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6861 (14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (95% CI 8 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability (withdrawal due to adverse events)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> <p><b>(172 to 210)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.07 (0.04 to 0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7029 (15 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 14 (95% CI 10 to 25)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (serious adverse events)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p><b>(16 to 20)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.00 (‐0.01 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6732 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>1,2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not calculated due to lack of statistically significant difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : Confidence interval; <b>FIQ</b> : Fibromyalgia Impact Questionnaire; <b>MFI</b> : Multidimensional Fatigue Inventory; <b>MOS‐Sleep problem index</b> : Medical Outcome Study ‐ sleep problem index; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harm; <b>NRS</b> : numerical rating scale; <b>RD</b> : risk difference; <b>SMD</b> : standardized mean difference; <b>VAS</b>: visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once: indirectness: participants with major medical diseases and mental disorders except major depression excluded in &gt; 50% of studies<br/><sup>2</sup>Downgraded once: publication bias<br/><sup>3</sup><a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>: N = 401 participants; MFI NRS 20‐100 scale<br/><sup>4</sup><a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>: N = 223 participants; MOS Sleep problem index NRS 0‐100 scale<br/><sup>5</sup><a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; N = 509 participants; FIQ VAS 0‐80 scale<br/><sup>6</sup>Downgraded once: imprecision due to low event rate </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010292-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010292-sec-0009"></div> <section id="CD010292-sec-0010"> <h3 class="title" id="CD010292-sec-0010">Description of the condition</h3> <p>Fibromyalgia is defined by the American College of Rheumatology (ACR) 1990 classification criteria as widespread pain lasting for longer than three months with tenderness on palpation at 11 or more of 18 specified tender points (<a href="./references#CD010292-bbs2-0125" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , Goldenberg DL et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(12):1863-4.">Wolfe 1990</a>). Chronic widespread pain is frequently associated with other symptoms, such as poor sleep, fatigue, and depression (<a href="./references#CD010292-bbs2-0129" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care &amp; Research2013;64:777-85.">Wolfe 2013a</a>). People with moderate and severe forms of fibromyalgia often report high disability levels and poor quality of life along with extensive use of medical care (<a href="./references#CD010292-bbs2-0085" title="HäuserW , AblinJ , FitzcharlesMA , LittlejonJ , LucianoJV , Usui C et al. Fibromyalgia. Nature Reviews Disease Primers2015;1:15022.">Häuser 2015a</a>; <a href="./references#CD010292-bbs2-0087" title="HäuserW , ClauwD , PerrotS , FitzcharlesMA . Unravelling fibromyalgia – steps towards individualized management. Journal of Pain2018;19:125-34.">Häuser 2017</a>). Fibromyalgia symptoms can be assessed by patient self‐report using the fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia (so‐called Fibromyalgia Symptom Questionnaire) (<a href="./references#CD010292-bbs2-0127" title="WolfeF , HäuserW , HassettAL , KatzRS , WalittBT . The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain2011;152(2):291-9.">Wolfe 2011a</a>). For a clinical diagnosis, the ACR 1990 classification criteria (<a href="./references#CD010292-bbs2-0125" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , Goldenberg DL et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(12):1863-4.">Wolfe 1990</a>), the ACR 2010 preliminary diagnostic criteria (<a href="./references#CD010292-bbs2-0126" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , Mease P et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis and Rheumatism2010;62(5):600-10.">Wolfe 2010</a>) and the 2016 criteria (<a href="./references#CD010292-bbs2-0131" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , Katz RL et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism2016;46:319-29.">Wolfe 2016</a>) can be used. Lacking a specific laboratory test, diagnosis is established by a history of the key symptoms and the exclusion of somatic diseases sufficiently explaining the key symptoms (<a href="./references#CD010292-bbs2-0126" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , Mease P et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis and Rheumatism2010;62(5):600-10.">Wolfe 2010</a>). For epidemiology studies, the modified ACR 2010 preliminary diagnostic criteria (survey criteria) can be used (<a href="./references#CD010292-bbs2-0127" title="WolfeF , HäuserW , HassettAL , KatzRS , WalittBT . The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain2011;152(2):291-9.">Wolfe 2011a</a>). </p> <p>The indexing of fibromyalgia within the international classification of diseases is under debate. While some rheumatologists have thought of it as a specific pain disorder and central sensitivity syndrome (<a href="./references#CD010292-bbs2-0058" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311:1547-55.">Clauw 2014</a>; <a href="./references#CD010292-bbs2-0135" title="YunusMB . Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism2008;37:339-52.">Yunus 2008</a>), recent research points at small fibre pathology in a subgroup of people with fibromyalgia that may be of pathophysiological importance (<a href="./references#CD010292-bbs2-0136" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , Sarholz M et al. Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz2017;31:239-45.">Üceyler 2017 a</a>). In psychiatry and psychosomatic medicine, fibromyalgia symptoms are categorized as a functional somatic syndrome, a bodily distress syndrome, a physical symptom disorder, or a somatoform disorder (<a href="./references#CD010292-bbs2-0076" title="HäuserW , EichW , HerrmannM , NutzingerDO , SchiltenwolfM , HenningsenP . Fibromyalgia syndrome: classification, diagnosis, and treatment [Fibromyalgiesyndrom: klassifikation, diagnose und therapie]. Deutsches Ärzteblatt International 2009;106(23):383-91.">Häuser 2009</a>; <a href="./references#CD010292-bbs2-0084" title="HäuserW , HenningsenP . Fibromyalgia syndrome - a somaform disorder. European Journal of Pain2014;18:1052-9.">Häuser 2014</a>). </p> <p>Fibromyalgia is a heterogeneous condition. The definite etiology (causes) of this syndrome remains unknown. A model of interacting biological and psychosocial variables in the predisposition, triggering and development of the chronicity of fibromyalgia symptoms has been suggested (<a href="./references#CD010292-bbs2-0136" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , Sarholz M et al. Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz2017;31:239-45.">Üceyler 2017 a</a>)). Inflammatory rheumatoid arthritis (<a href="./references#CD010292-bbs2-0127" title="WolfeF , HäuserW , HassettAL , KatzRS , WalittBT . The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain2011;152(2):291-9.">Wolfe 2011a</a>), depression (<a href="./references#CD010292-bbs2-0055" title="ChangMH , HsuJW , HuangKL , SuTP , BaiYM , Yang AC et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. Journal of Pain2015;16:895-902.">Chang 2015</a>), genetics (<a href="./references#CD010292-bbs2-0048" title="ArnoldLM , PalmerRH , MaY . A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clinical Journal of Pain2013;29:1021-8.">Arnold 2013</a>; <a href="./references#CD010292-bbs2-0091" title="LeeYH , ChoiSJ , JiJD , SongGG . Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International2012;32:417-26.">Lee 2012</a>), obesity combined with physical inactivity (<a href="./references#CD010292-bbs2-0104" title="MorkPJ , VasseljenO , NilsenTI . Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care &amp; Research2010;62:611-7.">Mork 2010</a>), physical and sexual abuse in childhood (<a href="./references#CD010292-bbs2-0077" title="HäuserW , KossevaM , UceylerN , KloseP , SommerC . Emotional, physical and sexual abuse in fibromyalgia syndrome - a systematic review with meta-analysis. Arthritis Care and Research2011;63(8):808-20.">Häuser 2010a</a>), sleep problems (<a href="./references#CD010292-bbs2-0105" title="MorkPJ , NilsenTI . Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis &amp; Rheumatism2012;64:281-4.">Mork 2012</a>), and smoking (<a href="./references#CD010292-bbs2-0056" title="ChoiCJ , KnutsenR , OdaK , FraserGE , KnutsenSF . The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. The Journal of Pain2010;11:994-1003.">Choi 2010</a>) predict future development of fibromyalgia. Psychosocial stress (e.g. working place and family conflicts) and physical stress (e.g. infections, surgery, accidents) might trigger the onset of chronic widespread pain and fatigue (<a href="./references#CD010292-bbs2-0058" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311:1547-55.">Clauw 2014</a>; <a href="./references#CD010292-bbs2-0136" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , Sarholz M et al. Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz2017;31:239-45.">Üceyler 2017 a</a>). Depression and post‐traumatic stress disorder worsen fibromyalgia symptoms (<a href="./references#CD010292-bbs2-0082" title="HäuserW , GalekA , Erbslöh-MöllerB , KöllnerV , Kühn-BeckerH , Langhorst J et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain2013;154:1216-23.">Häuser 2013 a</a>; <a href="./references#CD010292-bbs2-0090" title="LangeM , PetermannF . Influence of depression on fibromyalgia: a systematic review. Schmerz2010;24:326-33.">Lange 2010</a>). </p> <p>Several factors are associated with the pathophysiology (functional changes associated with or resulting from disease) of fibromyalgia, but the relationship is unclear. The functional changes include alteration of sensory processing in the brain (so‐called central sensitization), reduced reactivity of the hypothalamus‐pituitary‐adrenal axis to stress, increased pro‐inflammatory and reduced anti‐inflammatory cytokine profiles (produced by cells involved in inflammation), disturbances in neurotransmitters such as dopamine and serotonin and small nerve fibre pathology (<a href="./references#CD010292-bbs2-0136" title="ÜçeylerN , BurgmerM , FriedelE , GreinerW , PetzkeF , Sarholz M et al. Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz2017;31:239-45.">Üceyler 2017 a</a>). Prolonged exposure to stress, as outlined above, may contribute to these functional changes in predisposed individuals (<a href="./references#CD010292-bbs2-0053" title="BradleyLA . Pathophysiology of fibromyalgia. American Journal of Medicine2009;122(12 Suppl):S22-30.">Bradley 2009</a>). </p> <p>Fibromyalgia is common. Numerous studies have investigated its prevalence in different settings and countries. A review gives a global mean prevalence of 2.7% (range 0.4% to 9.3%), and a mean in the Americas of 3.1%, in Europe of 2.5% and in Asia of 1.7%. It is more common in women, with a female to male ratio of 3:1 (4.2%:1.4%) (<a href="./references#CD010292-bbs2-0112" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17:356.">Queiroz 2013</a>). Estimates of prevalence in specific populations vary greatly, but have been reported as being as high as 9% in female textile workers in Turkey and 10% in metalworkers in Brazil (<a href="./references#CD010292-bbs2-0112" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17:356.">Queiroz 2013</a>).The change in diagnostic criteria does not appear to have significantly affected estimates of prevalence (<a href="./references#CD010292-bbs2-0129" title="WolfeF , BrählerE , HinzA , HäuserW . Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care &amp; Research2013;64:777-85.">Wolfe 2013a</a>). </p> <p>Since specific treatment aimed at altering the pathogenesis is not possible, drug therapy that focuses on symptom reduction is ubiquitously employed. </p> </section> <section id="CD010292-sec-0011"> <h3 class="title" id="CD010292-sec-0011">Description of the intervention</h3> <p>Serotonin and noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) act on noradrenergic and serotonergic neurons in the nervous system. Serotonin and noradrenaline are implicated in the mediation of endogenous pain inhibitory mechanisms. </p> </section> <section id="CD010292-sec-0012"> <h3 class="title" id="CD010292-sec-0012">How the intervention might work</h3> <p>Dysfunction of serotonin and noradrenaline transmission, which mediates endogenous analgesic mechanisms via the descending inhibitory pain pathways in the central nervous system, may play a key role in the pathophysiology of fibromyalgia. Researchers found that levels of metabolites of biogenic amines key to descending inhibition were lower than normal in at least three fibromyalgia body fluid compartments (<a href="./references#CD010292-bbs2-0093" title="LegangneuxE , MoraJJ , Spreux-VaroquauxO , ThorinI , HerrouM , Alvado G et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology2001;40(3):290-6.">Legangneux 2001</a>; <a href="./references#CD010292-bbs2-0116" title="RussellIJ , VaeroyH , JavorsM , NybergF . Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and Rheumatism1992;35(5):550-6.">Russell 1992</a>). Imbalance or deficiency in serotonin and noradrenaline is also associated with other key symptoms of fibromyalgia such as fatigue and cognitive deficits (<a href="./references#CD010292-bbs2-0053" title="BradleyLA . Pathophysiology of fibromyalgia. American Journal of Medicine2009;122(12 Suppl):S22-30.">Bradley 2009</a>). Treatment with SNRI increases transmission of these neurotransmitters and may improve disease states associated with serotonin and noradrenaline deficiencies such as pain, fatigue and cognitive deficits. </p> </section> <section id="CD010292-sec-0013"> <h3 class="title" id="CD010292-sec-0013">Why it is important to do this review</h3> <p>There is a transatlantic difference in the approval of SNRIs as a treatment for fibromyalgia by drug agencies (<a href="./references#CD010292-bbs2-0054" title="BrileyM . Drugs to treat fibromyalgia - the transatlantic difference. Current Opinion in Investigational Drugs2010;11(1):16-8.">Briley 2010</a>). The SNRIs duloxetine and milnacipran have been approved by the US Food and Drug Administration (FDA), but not by the European Medical Agencies (EMA), for the management of fibromyalgia. The FDA stated that the sponsors of the two drugs had provided adequate evidence of their benefits and harms to support their indication for the management of fibromyalgia (<a href="./references#CD010292-bbs2-0063" title="Department of health &amp; Human Services. NDA Approval. www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022148s000ltr.pdf June 13, 2008.">Department of health &amp; Human Services 2008</a>; <a href="./references#CD010292-bbs2-0064" title="Department of health &amp; Human Services. NDA approval. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022256ltr.pdf January 14,2009.">Department of health &amp; Human Services 2009</a>). The EMA, however, denied clinically relevant effects for both drugs, on the basis of a lack of robust evidence of efficacy, and because the adverse effects profile was considered to outweigh the benefits (<a href="./references#CD010292-bbs2-0067" title="European Medicines Agency. Refusal assessment report for Cymbalta. International non-proprietary name/common name: (duloxetine hydrochloride) Procedure No. EMEA/H/C/572/II/26. Available at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000572/WC500076168.pdf Accessed 30 July 2009.">EMA 2008</a>; <a href="./references#CD010292-bbs2-0068" title="European Medicines Agency. Refusal assessment report for milnacipran Pierre Fabre Medicament. International non-proprietary name: milnacipran. Procedure No. EMEA/H/C/001034. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001034/WC500089828.pdf Accessed 30 July 30 2010.">EMA 2010</a>). We conducted a systematic review on SNRIs in fibromyalgia which included randomized controlled trials that had not been evaluated by the FDA and EMA in 2013 (<a href="./references#CD010292-bbs2-0083" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292]">Häuser 2013 b</a>). Meanwhile, new randomized controlled trials with duloxetine (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>), and milnacipran (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>), were published that had not been evaluated by the FDA and EMA and by the previous version of this review (<a href="./references#CD010292-bbs2-0083" title="HäuserW , UrrútiaG , TortS , UçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292]">Häuser 2013 b</a>). With new data available, and in the light of the divergent appraisals of duloxetine and milnacipran by the FDA and EMA, we saw the need to evaluate the efficacy and safety of SNRIs according to recently established methodological standards of pain medicine (<a href="./references#CD010292-bbs2-0100" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , Straube S et al. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9.'>Moore 2010a</a>), in order to assist people with fibromyalgia and doctors in shared decision making on pharmacological treatment options. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010292-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010292-sec-0014"></div> <p>To assess the efficacy, tolerability and safety of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010292-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010292-sec-0015"></div> <section id="CD010292-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010292-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included studies if they were double blind, randomized and controlled trials (RCTs) following four weeks of treatment (titration and maintenance) or longer. We included studies with a parallel, cross‐over and enriched enrolment randomized withdrawal (EERW) design. We included studies with a cross‐over design where (a) separate data from the two periods were reported, or (b) data were presented that excluded a statistically significant carry‐over effect, or (c) statistical adjustments were carried out in case of a significant carry‐over effect. Trials had to have at least 20 participants per treatment arm and had to report at least one of the outcomes of efficacy as defined below and of tolerability and safety as defined below. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non‐randomized, without control groups, studies of experimental pain, case reports, and clinical observations. </p> </section> <section id="CD010292-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (over 18 years) having a clinical diagnosis of fibromyalgia by any published, recognized and standardized criteria (<a href="./references#CD010292-bbs2-0118" title="SmytheHA . Fibrositis and other diffuse musculoskeletal syndromes. Textbook of Reumathology. 1st edition. Philadelphia: WB Saunders, 1981.">Smythe 1981</a>; <a href="./references#CD010292-bbs2-0125" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , Goldenberg DL et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(12):1863-4.">Wolfe 1990</a>; <a href="./references#CD010292-bbs2-0126" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , Mease P et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis and Rheumatism2010;62(5):600-10.">Wolfe 2010</a>; <a href="./references#CD010292-bbs2-0128" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , HäuserW , Katz RS et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology2011;38(6):1113-22.">Wolfe 2011b</a>, <a href="./references#CD010292-bbs2-0132" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a>; <a href="./references#CD010292-bbs2-0133" title="YunusM , MasiAT , CalabroJJ , ShahIK . Primary fibromyalgia. American Family Physician1982;25(5):115-21.">Yunus 1982</a>; <a href="./references#CD010292-bbs2-0134" title="YunusMB . Primary fibromyalgia syndrome: current concepts. Comprehensive Therapy1984;10(8):21-8.">Yunus 1984</a>). </p> </section> <section id="CD010292-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing SNRIs with placebo or another active drug with proven efficacy to reduce fibromyalgia symptoms. </p> <p>We allowed co‐interventions, such as physical therapy or other drugs different from those being assessed in the trial. </p> <p>We considered the following SNRIs in this review: desvenlafaxine, duloxetine, milnacipran, venlafaxine </p> </section> <section id="CD010292-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We followed some suggestions of the OMERACT Fibromyalgia Working Group (<a href="./references#CD010292-bbs2-0097" title="MeaseP , ArnoldLM , ChoyEH , ClauwDJ , CroffordLJ , Glass JM et al (the OMERACT Fibromyalgia Working Group). Fibromyalgia syndrome module at OMERACT 9: domain construct. Journal of Rheumatology2009;36(10):2318-29.">Mease 2009a</a>), the Initiative of Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD010292-bbs2-0066" title="DworkinRH , TurkDC , McDermottMP , Peirce-SandnerS , BurkeLB , Cowan P et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain2009;146(3):238-44.">Dworkin 2009</a>), and of best practice in the reporting of systematic reviews in chronic pain (<a href="./references#CD010292-bbs2-0100" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , Straube S et al. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9.'>Moore 2010a</a>; <a href="./references#CD010292-bbs2-0101" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , Wiffen P et al, ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173-6.">Moore 2010b</a>), for selecting outcome measures. </p> <section id="CD010292-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010292-list-0001"> <li> <p>Self‐reported pain relief of 50% or greater. Number of participants who reported a pain relief of 50% or greater in parallel and cross‐over design studies. For EERW design, loss of therapeutic response of self‐reported pain relief was defined as less than 30% reduction in visual analog scale (VAS) pain from pre‐drug exposure or worsening of fibromyalgia requiring alternative treatment. </p> </li> <li> <p>Patient perceived global improvement (Patient Global Impression of Change (PGIC), or Clinical Global Impression (CGI) of severity): number of participants who reported to be much or very much improved for parallel and cross‐over design studies; number of participants who reported a loss of therapeutic response to be much or very much improved in studies with EERW design. </p> </li> <li> <p>Tolerability (withdrawals due to adverse events)</p> </li> <li> <p>Safety (serious adverse events)</p> </li> </ul> </p> </section> <section id="CD010292-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010292-list-0002"> <li> <p>Self‐reported fatigue. We used the following preference: validated combined scale (e.g. Multidimensional Fatigue Inventory (MFI), Fatigue Severity Scale (FSS), Multidimensional Assessment of Fatigue (MAF) or other validated scales) over single item scales (e.g. Fibromyalgia Impact Questionnaire (FIQ) fatigue VAS, or other single item scales). We selected reduction of self‐reported fatigue as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported fatigue in studies with an EERW design. </p> </li> <li> <p>Self‐reported sleep problems. We used the following preference: validated combined scale (e.g. Medical Outcomes Study (MOS) sleep scale, or other validated scales), over single item assessment (e.g. FIQ sleep VAS, or other single item scales). We selected reduction of self‐reported sleep problems as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported sleep problems in studies with an EERW design. </p> </li> <li> <p>Self‐reported health‐related quality of life (HRQoL) measured by the total score of the Fibromyalgia Impact Questionnaire (FIQ). We selected improvement of self‐reported HRQoL as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported HRQoL in studies with an EERW design. </p> </li> <li> <p>Self‐reported pain relief of 30% or greater. There was no comparable outcome in studies with an EERW design. </p> </li> <li> <p>Self‐reported mean pain intensity. We used the following preferences: (a) we preferred electronic diaries over paper; (b) 24‐hour recall pain, weekly recall pain with visual analog scale (VAS); (c) paper VAS, paper numeric 11‐point ordinal scale (Numeric Rating Scale NRS), combined pain measures, pain drawings. We selected reduction of self‐reported mean pain intensity as the outcome for studies with a parallel and cross‐over design. There was no comparable outcome in studies with an EERW design. </p> </li> <li> <p>Self‐reported depression. We used the following preference: validated combined scale (Beck Depression Inventory (BDI), or other validated scales), over single‐item assessment (e.g. FIQ subscale for depression, or other single item scales). We selected reduction of self‐reported depression as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported depression in studies with an EERW design. </p> </li> <li> <p>Self‐reported anxiety. We used the following preference: validated combined scale (Beck Anxiety Inventory (BAI), State Trait Anxiety Inventory (STAI), or other validated scales), over single item scale (FIQ anxiety VAS, or other single item scales). We selected reduction of self‐reported anxiety as the outcome for studies with a parallel and cross‐over design and loss of therapeutic response of self‐reported anxiety in studies with an EERW design. </p> </li> <li> <p>Self‐reported disability (impairment of physical function). We used the following preference: validated combined scale (Brief Pain Inventory (BPI) interference from pain, Short‐Form Health Survey (SF‐36) physical summary score, or other validated scales), over single item scale (FIQ physical impairment VAS, or other single item scales). We selected reduction of self‐reported disability as an outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported disability in studies with an EERW design. </p> </li> <li> <p>Self‐reported sexual function. We used the following preference: validated combined scale (Arizona Sexual Experience Scale, or other validated scale), over single item scale. We selected reduction of self‐reported sexual problems as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported sexual problems in studies with an EERW design. </p> </li> <li> <p>Self‐reported cognitive disturbances: validated combined scale (Multiple Ability Self‐report Questionnaire (MASQ), or any other validated scale), over single item scale. We selected reduction of self‐reported cognitive disturbances as the outcome for studies with a parallel and cross‐over design, and loss of therapeutic response of self‐reported cognitive disturbances in studies with an EERW design. </p> </li> <li> <p>Tenderness: measurement of tender point pain threshold</p> </li> <li> <p>Number of participants dropping out due to lack of efficacy</p> </li> <li> <p>Specific adverse events frequently associated with the use of SNRIs (nausea, somnolence, insomnia) </p> </li> </ul> </p> </section> </section> </section> <section id="CD010292-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010292-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We ran three searches for the update, with the first in November 2015, the second in August 2016 and the third in August 2017. For this update we searched: </p> <p> <ul id="CD010292-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 7) in the Cochrane Library; </p> </li> <li> <p>MEDLINE accessed through PubMed (Sept 2012 to August 2017);</p> </li> <li> <p>Embase accessed through SCOPUS (Sept 2012 to August 2017).</p> </li> </ul> </p> <p>See <a href="./appendices#CD010292-sec-0172">Appendix 1</a> for details of all search strategies used. There were no language or date restrictions. </p> </section> <section id="CD010292-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the websites of the US National Institute of Health (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) to August 2017 for ongoing trials. We searched bibliographies from reviewed articles and we retrieved relevant articles. Our search included all languages. We contacted content experts for unpublished and further possible studies. </p> </section> </section> <section id="CD010292-sec-0026"> <h3 class="title" id="CD010292-sec-0026">Data collection and analysis</h3> <section id="CD010292-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (WH, BW) independently scrutinized all the titles and abstracts revealed by the searches and determined which fulfilled the selection criteria. A third review author (NÜ) verified that the selection had been properly realized. </p> </section> <section id="CD010292-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (NÜ, PW, WH) extracted data independently onto a specially designed data extraction form. We would have resolved any disagreements by discussion with the third review author (BW), but this was not necessary. One author (WH) entered data into Review Manager 5 (RevMan 5) (<a href="./references#CD010292-bbs2-0114" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and two authors (NÜ,PW) checked them. We resolved discrepancies by discussion. </p> </section> <section id="CD010292-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NÜ,WH) independently assessed the risk of bias of each included trial. We resolved disagreements by consensus and, if needed, referral to a third review author (BW). </p> <p>We assessed the following risks of bias for each study.</p> <p> <ul id="CD010292-list-0004"> <li> <p><b>Random sequence generation</b> (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, for example random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (for example, odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p><b>Allocation concealment</b> (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (for example, telephone or central randomization; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). </p> </li> <li> <p><b>Blinding of participants and personnel/treatment providers</b> (systematic performance bias). We assessed the methods used to blind participants and personnel/treatment providers from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, for example, identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved); high risk (blinding of participants was not ensured, e.g. tablets different in form or taste). </p> </li> <li> <p><b>Blinding of outcome assessment</b> (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that outcome assessors were blinded to the intervention or exposure status of participants; unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved); high risk: outcome assessors knew the intervention or exposure status of participants. </p> </li> <li> <p><b>Incomplete outcome data</b> (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (fewer than 10% of participants did not complete the study or used ’baseline observation carried forward’ analysis, or both); unclear risk of bias (used ’last observation carried forward’ (LOCF) analysis); or high risk of bias (used ’completer’ analysis). </p> </li> <li> <p><b>Reporting bias due to selective outcome reporting</b> (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. There is low risk of reporting bias if the study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way, or if the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon). There is a high risk of reporting bias if not all of the study’s prespecified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (for example, subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study. </p> </li> <li> <p><b>Group similarity at baseline</b> (selection bias). We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. There is low risk of bias if groups are similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors. There is high risk of bias if groups are not similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factor. </p> </li> <li> <p><b>Size of study</b> (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ul> </p> <p>We defined studies with no to two unclear or high risks of bias to be high‐quality studies, with three to five unclear or high risks of bias to be moderate‐quality studies and with six to eight unclear or high risks of bias to be low‐quality studies (<a href="./references#CD010292-bbs2-0086" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , KoppI . Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain. Schmerz2015;29:8-34.">Häuser 2015b</a>). </p> </section> <section id="CD010292-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>Our effect measures of choice were risk differences (RD) for dichotomous data and standardized mean difference (SMD) for continuous data (using the inverse variance method). We used a random‐effects model because we assumed that clinical heterogeneity would be present. We expressed uncertainty using 95% confidence intervals (CIs). </p> <p>We calculated number needed to treat for an additional beneficial outcome (NNTB) as the reciprocal of the absolute risk reduction (ARR). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. For drop outs due to lack of efficacy, NNTp becomes the number of participants needed to prevent an additional unwanted outcome and is calculated in the same manner. For dichotomous data we calculated risk differences (RDs). The threshold for 'clinically relevant benefit' or 'clinically relevant harm' was set for categorical variables by an absolute risk reduction or increase of 10% or greater, corresponding to a NNTB or NNTH of 10 or less (<a href="./references#CD010292-bbs2-0099" title="MooreRA , BardenJ , DerryS , McQuayHJ . Systematic Reviews in Pain Research: Methodology Refined. 1st edition. Washington: IASP Press, 2008.">Moore 2008</a>). </p> <p>We used Cohen’s categories to evaluate the magnitude of the effect size, calculated by SMD, with values for Hedges' g as follows: 0.2 to 0.5 equating to a small effect size, 0.5 to 0.8 equating to a medium effect size, and more than 0.8 equating to a large effect size (<a href="./references#CD010292-bbs2-0059" title="CohenJ . Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, 1988.">Cohen 1988</a>). We considered values of g less than 0.2 to equate to a 'not substantial' effect size (<a href="./references#CD010292-bbs2-0086" title="HäuserW , KloseP , WelschP , PetzkeF , NothackerM , KoppI . Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain. Schmerz2015;29:8-34.">Häuser 2015b</a>). The threshold ’clinically relevant benefit’ was set for continuous variables by an effect size more than 0.2 (<a href="./references#CD010292-bbs2-0069" title="FayersPM , HaysRD . Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Research2014;23:1-4.">Fayers 2014</a>). </p> <p>We calculated the NNTBs for continuous variables (fatigue, sleep problems, HRQoL) using the Wells calculator software available at the Cochrane Musculoskeletal Group editorial office, which estimates, from the SMDs, the proportion of participants who will benefit from treatment if there was a statistically significant (P value ≤ 0.05) difference between SNRIs and control group (<a href="./references#CD010292-bbs2-0108" title="NormanGR , SridharFG , GuyattGH , WalterSD . Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care2001;39(10):1039-47.">Norman 2001</a>). We used a minimally important difference (MID) of 0.5 for calculation. </p> <p>We calculated measures of treatment effect if at least two studies with at least 200 participants were available. </p> </section> <section id="CD010292-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In trials comparing multiple SNRI‐dosage arms with one placebo group, for continuous outcomes we adjusted the number of participants in the placebo group according to the number of participants in the different SNRI‐dosage arms. For dichotomous variables we pooled the different SNRI dosage arms and compared the pooled results with the placebo arm. </p> </section> <section id="CD010292-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis data. The ITT population consisted of participants who were randomized, took the assigned study medication, and provided at least one post‐baseline assessment. Wherever possible, we assigned zero improvement to missing participants. However, most studies in chronic pain report results, including responder results, using last observation carried forward. This has been questioned as being potentially biased, as withdrawal is an important outcome that makes last observation carried forward unreliable. Last observation carried forward can lead to overestimation of efficacy, particularly in situations where adverse event withdrawal rates differ between active and control groups. At this time it is unclear what strategy can actually be used to deal with missing data inside studies (<a href="./references#CD010292-bbs2-0103" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , Wiffen P et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153:265-8.">Moore 2012</a>). We examined and reported imputation strategies clearly. </p> <p>Where means or SDs were missing, we attempted to obtain these data through contacting trial authors for the first version, but not for the update of the review. Where SDs were not available from trial authors, we calculated them from t‐values, CIs or standard errors, where reported in articles (<a href="./references#CD010292-bbs2-0075" title="HigginsJPT , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Where rates of pain relief of 30% and 50% or greater were not reported and not provided on request, we calculated them from means and SDs by a validated imputation method (<a href="./references#CD010292-bbs2-0071" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52.">Furukawa 2005</a>). </p> </section> <section id="CD010292-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic for heterogeneity (<a href="./references#CD010292-bbs2-0073" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). I<sup>2</sup> statistic values less than 25% indicate low heterogeneity; values of 25% to 50% indicate moderate heterogeneity, and values of 50% or over indicate substantial heterogeneity (<a href="./references#CD010292-bbs2-0062" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). </p> </section> <section id="CD010292-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher) (<a href="./references#CD010292-bbs2-0099" title="MooreRA , BardenJ , DerryS , McQuayHJ . Systematic Reviews in Pain Research: Methodology Refined. 1st edition. Washington: IASP Press, 2008.">Moore 2008</a>). </p> </section> <section id="CD010292-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook each meta‐analysis using a random‐effects model in RevMan 5 (<a href="./references#CD010292-bbs2-0114" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD010292-sec-0036"> <h4 class="title">Quality of evidence</h4> <p>Two review authors (NÜ, WH) independently rated the quality of the outcomes. We used the GRADE system to rank the quality of the evidence using the GRADEprofiler Guideline Development Tool software (<a href="./references#CD010292-bbs2-0072" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.Available at gradepro.org.">GRADEpro GDT</a>), and the guidelines provided in Chapter 12.2 of the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010292-bbs2-0117" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , Glasziou P et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). </p> <p>The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence. </p> <p> <ul id="CD010292-list-0005"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </li> </ul> </p> <p>The GRADE system uses the following criteria for assigning a quality level to a body of evidence (Chapter 12, <a href="./references#CD010292-bbs2-0117" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , Glasziou P et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). </p> <p> <ul id="CD010292-list-0006"> <li> <p>High: randomized trials; or double‐upgraded observational studies</p> </li> <li> <p>Moderate: downgraded randomized trials; or upgraded observational studies</p> </li> <li> <p>Low: double‐downgraded randomized trials; or observational studies</p> </li> <li> <p>Very low: triple‐downgraded randomized trials; or downgraded observational studies; or case series/case reports </p> </li> </ul> </p> <p>Factors that may decrease the quality level of a body of evidence are as follows.</p> <p> <ul id="CD010292-list-0007"> <li> <p>limitations in the design and implementation of available studies suggesting high likelihood of bias. We assumed that there were limitations in study design if more than 50% of participants were from low‐quality studies, as defined by the 'Risk of bias' tool; </p> </li> <li> <p>indirectness of evidence (indirect population, intervention, control, outcomes). We assessed whether the question being addressed by the systematic review diverged from the available evidence, in terms of the population in routine clinical care, if exclusion of participants with clinically relevant somatic disease (e.g. inflammatory rheumatic diseases) and/or depressive and anxiety disorders in the included studies resulted in 50% or more of the total participant collective of the systematic review coming from studies in which participants with clinically relevant somatic disease (e.g. inflammatory rheumatic diseases) and/or depressive and anxiety disorders had been excluded; </p> </li> <li> <p>unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); </p> </li> <li> <p>imprecision of results (wide confidence intervals);</p> </li> <li> <p>high probability of publication bias. We assumed a publication bias if all studies were initiated and funded by the manufacturer of the drug. </p> </li> </ul> </p> <p>Factors that may increase the quality level of a body of evidence are:</p> <p> <ul id="CD010292-list-0008"> <li> <p>large magnitude of effect;</p> </li> <li> <p>all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect; </p> </li> <li> <p>dose‐response gradient.</p> </li> </ul> </p> <p>We decreased the grade rating by one (‐ 1) or two (‐ 2) (up to a maximum of ‐ 3 to 'very low') if we identified: </p> <p> <ul id="CD010292-list-0009"> <li> <p>serious (‐ 1) or very serious (‐ 2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐ 1);</p> </li> <li> <p>some (‐ 1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐ 1);</p> </li> <li> <p>high probability of reporting bias (‐ 1).</p> </li> </ul> </p> <section id="CD010292-sec-0037"> <h5 class="title">'Summary of findings' table</h5> <p>We included a 'Summary of findings' table to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes. </p> <p>We included the following outcomes in the 'Summary of findings' table.</p> <p> <ul id="CD010292-list-0010"> <li> <p>Self‐reported pain relief 50% or greater</p> </li> <li> <p>Patient global impression to be much or very much improved</p> </li> <li> <p>Self‐reported fatigue</p> </li> <li> <p>Self‐reported sleep problems</p> </li> <li> <p>Self‐reported health‐related quality of life</p> </li> <li> <p>Withdrawal rates due to adverse events (tolerability)</p> </li> <li> <p>Serious adverse events (safety)</p> </li> </ul> </p> </section> </section> <section id="CD010292-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed a subgroup analysis of duloxetine, and milnacipran studies to test for potential differences in benefits and harms of these two drugs. We performed a subgroup analysis of studies with and without European participants to test for potential transatlantic differences between the efficacy and adverse events of SNRIs. A more detailed analysis of European versus non‐European participants was not possible because the studies with mixed continent samples did not report how many participants were recruited from each continent. We decided to restrict the comparisons on pain relief of 50% or greater and dropout due to adverse events in order not to inflate the number of comparisons. To test the hypotheses of a subgroup effect, we used a test of interaction with a predetermined, two‐tailed α value of 0.05 for subgroup analysis of studies with and without European participants (<a href="./references#CD010292-bbs2-0044" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219.">Altman 2003</a>). We did not conduct the intended subgroup analyses with gender and pain because individual participant data were not available. </p> </section> <section id="CD010292-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses (different statistical models applied, diagnostic criteria used in the trial, presence/absence of any mental or psychiatric disorder, and presence/absence of any concomitant systemic disease). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010292-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010292-sec-0040"></div> <section id="CD010292-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD010292-sec-0042"> <h4 class="title">Results of the search</h4> <p>In the previous review, one excluded study (Gendreau 2005) was incorrectly categorized, and should have been a secondary reference to <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>. The total number of studies excluded in the 2013 review was nine. The total number of included studies in the 2013 review was 10 (11 reports). </p> <p>The updated searches (last performed 8 August 2017) produced 214 records after duplicates were removed. We excluded 22 studies in total: we excluded nine in the 2013 review (<a href="./references#CD010292-bbs2-0021" title="BrancoJC , CherinP , MontagneA , BouroubiA , Multinational Coordinator Study Group. Long term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology2011;38:1403-12. ">Branco 2011</a>; <a href="./references#CD010292-bbs2-0022" title="ChappellAS , LittlejohnG , KajdaszDK , ScheinbergM , D’SouzaDN , MoldofskyH . A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clinical Journal of Pain2009;25:365-75. ">Chappell 2009b</a>; <a href="./references#CD010292-bbs2-0023" title="DwightMM , ArnoldLM , O’BrienH , MetzgerR , Morris-ParkE , Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics1998;39:14-7. ">Dwight 1998</a>; <a href="./references#CD010292-bbs2-0024" title="GoldenbergDL , ClauwDJ , PalmerRH , MeaseP , ChenW , GendreauRM . Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Medicine2010;11:180-94. ">Goldenberg 2010</a>; <a href="./references#CD010292-bbs2-0025" title="HsiaoMC . Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine. Primary Care Companion to the Journal of Clinical Psychiatry2007;9:398. ">Hsiao 2007</a>; <a href="./references#CD010292-bbs2-0026" title="MeasePJ , RussellIJ , KajdaszDK , WiltseCG , DetkeMJ , Wohlreich MM et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism2010;39:354-64. ">Mease 2010</a>; <a href="./references#CD010292-bbs2-0037" title="SaxePA , ArnoldLM , PalmerRH , GendreauRM , ChenW . Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Current Medical Research and Opinion2012;28(5):815-21. ">Saxe 2012</a>; <a href="./references#CD010292-bbs2-0038" title="SayarK , AksuG , AkI , TosunM . Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy2003;37:1561-5. ">Sayar 2003</a>; <a href="./references#CD010292-bbs2-0028" title="NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&amp;cond=fibromyalgia&amp;rank=4 First posted: August 29, 2006. ">NCT00369343</a>) (total corrected in this review), and 13 additional studies for the update (<a href="./references#CD010292-bbs2-0019" title="AhmedM , AamirR , JishiZ , ScharfMB . The effects of milnacipran on dleep fisturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study. Journal of Clinical Sleep Medicine2016;12:79-86. ">Ahmed 2016</a>; <a href="./references#CD010292-bbs2-0020" title="AngDC , JensenMP , SteinerJL , HilligossJ , GracelyRH , SahaC . Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clinical Journal of Pain2013;29:747-54. ">Ang 2013</a>; <a href="./references#CD010292-bbs2-0027" title="NatelsonBH , VuD , MaoX , WeiduschatN , TogoF , Lange G et al. Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:1211-9. ">Natelson 2015</a>; <a href="./references#CD010292-bbs2-0029" title="AllenR , SharmaU , BarlasS . Clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome. Clinical Pharmacology in Drug Development2017;6:224-33. NCT00725101. Fibromyalgia health outcome study on cost of treatments (REFLECTIONS). clinicaltrials.gov/ct2/results?term=NCT00725101&amp;Search=Search First Posted: July 30, 2008. ">NCT00725101</a>; <a href="./references#CD010292-bbs2-0030" title="NCT00793520. Effect of milnacipran on pain processing and functional magnetic resonance imaging (fMRI) activation patterns in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00793520&amp;Search=Search First posted: November 19,2008. ">NCT00793520</a>; <a href="./references#CD010292-bbs2-0031" title="NCT01108731. The effect of milnacipran in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01108731&amp;Search=Search First posted: April 22, 2010. ">NCT01108731</a>; <a href="./references#CD010292-bbs2-0032" title="NCT01173055. A study to evaluate the effects of milnacipran on pain processing and functional MRI in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01173055&amp;Search=Search First posted: July 30, 2010. ">NCT01173055</a>; <a href="./references#CD010292-bbs2-0033" title="NCT01234675. The effects of milnacipran on sleep disturbance in fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01234675&amp;Search=Search First posted: November 4, 2010. ">NCT01234675</a>; <a href="./references#CD010292-bbs2-0034" title="NCT01294059. Effects of milnacipran on widespread mechanical and thermal hyperalgesia of fibromyalgia patients. clinicaltrials.gov/ct2/results?term=NCT01294059&amp;Search=Search First posted: February 11, 2011. ">NCT01294059</a>; <a href="./references#CD010292-bbs2-0035" title="NCT01331109. Long-term safety and efficacy study of milnacipran in pediatric patients with primary fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01331109&amp;Search=Search First posted: April 7, 2011. ">NCT01331109</a>; <a href="./references#CD010292-bbs2-0036" title="NCT01621191. An extension study of duloxetine in fibromyalgia (extension of F1J-JE-HMGZ, NCT01552057). clinicaltrials.gov/ct2/results?term=NCT01621191&amp;Search=Search First posted: June 12, 2012. ">NCT01621191</a>; <a href="./references#CD010292-bbs2-0039" title="TrugmanJM , PalmerRH , MaY . Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Current Medical Research &amp; Opinion2014;30:589-97. ">Trugman 2014</a>; <a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>). One study with desvenlafaxine excluded in the 2013 review, available in clinicaltrials.gov and which did not report data suited for meta‐analysis (<a href="./references#CD010292-bbs2-0028" title="NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&amp;cond=fibromyalgia&amp;rank=4 First posted: August 29, 2006. ">NCT00369343</a>), was published in a peer‐reviewed journal in 2017. The published data were again not suited for meta‐analysis (Allen 2017, secondary reference to (<a href="./references#CD010292-bbs2-0028" title="NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&amp;cond=fibromyalgia&amp;rank=4 First posted: August 29, 2006. ">NCT00369343</a>). One study with venlafaxine which was not found in the search for the 2013 review (<a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>), was published in a peer‐reviewed journal in 2015 (vanDerWeide 2015, secondary reference to <a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>).The published data of both reports were not suited for meta‐analysis. See the <a href="./references#CD010292-sec-0197" title="">Characteristics of excluded studies</a> table for further details about reasons for exclusion and <a href="#CD010292-fig-0001">Figure 1</a> for the study flow diagram. </p> <div class="figure" id="CD010292-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010292-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Mohs 2012 is a secondary reference for <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>, which was an included study in the 2013 review; Mease 2014 is a secondary reference for <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>, an included study added at this update. </p> <p>We included eight new studies (nine reports) (<a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). </p> <p>In sum, we included 18 studies in the qualitative and quantitative analysis. See the <a href="./references#CD010292-sec-0196" title="">Characteristics of included studies</a> table for a full description of the studies. </p> </section> <section id="CD010292-sec-0043"> <h4 class="title">Included studies</h4> <p>We included eight studies with duloxetine (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>), nine studies with milnacipran (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>) and one study with desvenlafaxine (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>) in the analysis of placebo controlled trials. The eight studies with duloxetine included 11 study arms with different dosages of duloxetine. The studies with milnacipran contained 11 study arms with different dosages of milnacipran. Two studies were entered in the analysis of active drug controlled trials (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>), one with duloxetine (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>) and one with desvenlafaxine (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). One of these studies had three study arms (desvenlafaxine fixed dosage, pregabalin fixed dosage, placebo) (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). The studies included a total of 7903 participants. </p> <section id="CD010292-sec-0044"> <h5 class="title">Study characteristics</h5> <p>All studies were conducted in multiple research centers except three single‐center studies (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). Eight studies were conducted in the USA (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>, <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>), two studies each in the USA and Puerto Rico (<a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>) and in more than one continent (<a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>), one study each in the USA and Western Europe (<a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>), in the USA and Canada (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>) and in Japan (<a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>), and three studies in Europe (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>). All studies had a parallel design except one with an EERW design (<a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>). Study duration ranged between 6 and 12 weeks in 11 studies (short‐term studies) (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>) and between 13 and 26 weeks in four studies (medium‐term studies) (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). Two studies had a long‐term duration (&gt; 26 weeks) with 27 weeks each (<a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>). Two studies were started after 2010 (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>), the remaining studies were conducted between 2002 and 2010. </p> <p>All studies were funded by the manufacturer of the respective drug except one study that did not report details of funding (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>). There was no investigator‐initiated study or public funding. All authors but five (<a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>) declared potential conflicts of interest. Two authors (<a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>) stated that they had no potential financial conflict of interest. The remaining authors who declared conflicts of interest, reported to have received payments by the sponsor of the study for consultancies and/or owned stocks or were employees of the sponsor of the study. </p> </section> <section id="CD010292-sec-0045"> <h5 class="title">Participant characteristics</h5> <p>All studies included participants over 18 years old. Diagnosis of fibromyalgia was established by all studies by the ACR 1990 classification criteria (<a href="./references#CD010292-bbs2-0125" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , Goldenberg DL et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33(12):1863-4.">Wolfe 1990</a>). All studies required a pain score of more than 3 for inclusion except for <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a> and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>, which did not require a minimum pain score for inclusion. <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a> required a pain score of more than 4 for inclusion. <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a> required that participants reported no adequate reduction of fibromyalgia symptoms by previous treatment with duloxetine 60 mg a day. All studies excluded participants with somatic diseases, including inflammatory rheumatic diseases. All duloxetine studies included participants with mental disorders, except for major depression (all studies) and general anxiety disorder (all but one study <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>). All milnacipran studies excluded participants with severe mental disorders including major depression except <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>. Middle‐aged, white women prevailed in all studies: the median of the mean age was 49 years (range 47 to 55 years). The median of the percentage of women was 95% (range 82% to 100%). The median of the percentage of white people was 91% (range 0% to 97%). Three studies conducted in Europe (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>) and two studies conducted in USA (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>) did not report the ethnicity of the participants. The percentage of participants with major depressive disorder in the duloxetine studies ranged from 4% to 41%. A total of 4230 (mean 235; SD 55; minimum 23, maximum 795) participants were included in the active drug groups and 2997 (mean 167; SD 36; minimum 21, maximum 509) in the comparison groups. </p> </section> <section id="CD010292-sec-0046"> <h5 class="title">Interventions</h5> <p>Duloxetine dosage was fixed, with 30 mg a day in <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a> and <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>, 60 mg a day in <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a> and <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>, and 120 mg a day in <a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a> and <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>. Duloxetine dosage was flexible with 30 mg or 60 mg a day in <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a> and 60 mg or 120 mg a day in <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a> and <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>. Milnacipran dosage was fixed, with 100 mg a day in <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a> and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>, and with 200 mg a day in <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a> and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>, and flexible (100 mg or 200 mg a day) in <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a> and <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>. In addition, one study compared duloxetine 60 mg a day, fixed, with L‐carnitine 300 mg a day (<a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>), and one study compared desvenlafaxine 200 mg a day, fixed, with pregabalin 450 mg a day, fixed (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). The other studies had a single SNRI arm. The rescue medication in duloxetine trials was acetaminophen (paracetamol) up to 2 g a day and aspirin up to 325 mg a day, and in milnacipran trials was hydrocodone up to 60 mg a day. The desvenlafaxine study did not report on rescue medication (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0047"> <h5 class="title">Primary outcomes</h5> <section id="CD010292-sec-0048"> <h6 class="title">Self‐reported pain relief of 50% or greater</h6> <p>All studies used different measures for pain. We selected the predefined primary outcome variables of the studies for analysis. The duloxetine studies (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>) assessed pain using the Brief Pain Inventory (BPI) 24 average pain score except <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>, which used a VAS 0‐10. The milnacipran trials used the patient electronic diary 24‐hour recall pain score (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>) and the desvenlafaxine study used pain score numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable) (NRS 0‐10) across the last 24 hours and seven days (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0049"> <h6 class="title">Patient global impression much or very much improved</h6> <p>Patient global impression of change was assessed by all studies except three studies (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>). However, five studies reported only average scores, which could not be used for the predefined analysis (<a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>). The desvenlafaxine study did not assess this outcome (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0050"> <h6 class="title">Tolerability (withdrawals due to adverse events)</h6> <p>All studies reported the number of participants dropping out due to adverse events.</p> </section> <section id="CD010292-sec-0051"> <h6 class="title">Safety (serious adverse events)</h6> <p>Four studies reported no details at all of the assessment (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). The remaining studies used physical examination, electrocardiograms, and laboratory analysis for the assessment of adverse events<i>.</i> Four studies did not report details about how they had assessed subjective adverse symptoms (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>). Three studies reported the recording of spontaneously‐reported adverse events (<a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>), another two studies reported spontaneously‐reported and investigator‐observed adverse events (<a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>), and one study reported both spontaneously‐reported and investigator‐observed (use of non‐leading questions) adverse events (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>). Two studies used the Columbia Suicide Severity Scale to assess suicidality (<a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>). </p> </section> </section> <section id="CD010292-sec-0052"> <h5 class="title">Secondary outcomes</h5> <section id="CD010292-sec-0053"> <h6 class="title">Self‐reported fatigue</h6> <p>Fatigue was assessed either by the single item of the FIQ (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>), or by a VAS 0‐10 (<a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>) or by the Multidimensional Fatigue Inventory (MFI) (<a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>, <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>). One study assessed fatigue by a visual analog scale (VAS) from 0 to 100 (<a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). Two studies did not report the outcome (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>). One study did not assess this outcome (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>. </p> </section> <section id="CD010292-sec-0054"> <h6 class="title">Self‐reported sleep problems</h6> <p>The duloxetine studies, <a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a> and <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a> assessed sleep disturbances using the BPI sleep interference scale. However, three studies did not report the sleep outcomes (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>). The duloxetine studies of <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a> and <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a> did not assess sleep problems </p> <p>Sleep was assessed by the Medical Outcomes Study (MOS) in four milnacipran studies (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>;<a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>). The <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a> study used the Jenkins Sleep Scale. One milnacipran study did not report on the assessment of sleep outcomes (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>). The remaining milnacipran studies did not assess sleep problems (<a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). </p> <p>The study with desvenlafaxine did not assess this outcome (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0055"> <h6 class="title">Self‐reported health‐related quality of life</h6> <p>Two studies did not assess health‐related quality of life (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). The remaining studies except <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a> used the FIQ‐total score of which one study used the revised FIQ (<a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>). <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a> used the Short Form Health Survey SF‐36. One study did not report the FIQ total score ( <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>). </p> </section> <section id="CD010292-sec-0056"> <h6 class="title">Self‐reported pain relief of 30% or greater</h6> <p>All studies used different measures for pain. We selected the predefined primary outcome variables of the studies for analysis. The duloxetine studies (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>) assessed pain using the Brief Pain Inventory (BPI) 24 average pain score except <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>, which used a VAS 0 to 10 scale. The milnacipran trials assessed pain using the patient electronic diary 24‐hour recall pain score (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>). The desvenlafaxine study used a pain score numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable) (NRS 0‐10) across the last 24 hours and seven days (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0057"> <h6 class="title">Self‐reported mean pain intensity</h6> <p>All studies used different measures for pain. We selected the predefined primary outcome variables of the studies for analysis. The duloxetine studies (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>) assessed pain using the Brief Pain Inventory (BPI) 24 average pain score except <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>, which used a VAS 0 to 10 scale. The milnacipran trials assessed pain using the patient electronic diary 24‐hour recall pain score (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>). The desvenlafaxine study used a pain score numeric rating scale (NRS) from 0 (no pain) to 10 (worst pain imaginable) (NRS 0‐10) across the last 24 hours and seven days (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0058"> <h6 class="title">Self‐reported depression</h6> <p><a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a> used the Hamilton Depression Rating Scale (HDRS), <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a> the Hospital and Anxiety Depression Subscale Depression, <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a> and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a> used the FIQ single item depression scale and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a> a VAS 0 to 100 scale. The remaining studies used the Beck Depression Inventory (BDI). The desvenlafaxine study did not assess this outcome (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> </section> <section id="CD010292-sec-0059"> <h6 class="title">Self‐reported anxiety</h6> <p>Four studies used the Beck Anxiety Inventory (BAI) to assess anxiety (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>), two studies used the Stait‐Trait Anxiety Inventory (STAI) (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>), three studies used the FIQ single item scale (<a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>), and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a> used a VAS 0 to 100. The remaining studies, including the desvenlafaxine study (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>), did not assess this outcome. </p> </section> <section id="CD010292-sec-0060"> <h6 class="title">Self‐reported disability</h6> <p>We used the BPI average interference scale as a measure of disability in six studies with duloxetine (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). The remaining seven studies used three different measures for disability/physical function, namely subscale data of: Multidimensional Health Assessment Questionnaire (MDHAQ) (<a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>), the Short Form Health Survey physical component summary score (<a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>); and the FIQ single item subscale <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>). One study did not report the FIQ single item subscale score (<a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>). Two studies did not assess this outcome (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>). </p> </section> <section id="CD010292-sec-0061"> <h6 class="title">Self‐reported sexual function</h6> <p>Only three studies reported on the assessment of sexual function by the Arizona Sexual Experience Scale. However, one study did not report the data (<a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>), and the other did not report the SDs (<a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>). Only one study reported outcomes suitable for meta‐analysis (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>). </p> </section> <section id="CD010292-sec-0062"> <h6 class="title">Self‐reported cognitive disturbances</h6> <p>Three duloxetine studies assessed cognitive disturbances ('fibro fog') using the mental fatigue subscale of the MFI (<a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>), five milnacipran studies, using the Multiple Ability Self‐report Questionnaire (MASQ) (<a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>). </p> </section> <section id="CD010292-sec-0063"> <h6 class="title">Tender point pain threshold</h6> <p>Only four duloxetine studies measured tender point pain threshold (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). </p> </section> <section id="CD010292-sec-0064"> <h6 class="title">Dropout due to lack of efficacy</h6> <p>All the included studies reported this outcome except <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a> and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>. </p> </section> <section id="CD010292-sec-0065"> <h6 class="title">Specific adverse events</h6> <section id="CD010292-sec-0066"> <p><b>Nausea</b></p> <p>All the included studies reported this adverse event except <a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>. </p> </section> <section id="CD010292-sec-0067"> <p><b>Somnolence</b></p> <p>All the duloxetine studies except <a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a> reported this adverse event, as well as the desvenlafaxine study (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). None of the studies with milnacipran reported on this outcome. </p> </section> <section id="CD010292-sec-0068"> <p><b>Insomnia</b></p> <p>All the included studies reported this adverse event except <a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>. </p> </section> </section> </section> </section> <section id="CD010292-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 studies in total. Five studies had fewer than 20 participants per treatment arm (<a href="./references#CD010292-bbs2-0019" title="AhmedM , AamirR , JishiZ , ScharfMB . The effects of milnacipran on dleep fisturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study. Journal of Clinical Sleep Medicine2016;12:79-86. ">Ahmed 2016</a>; <a href="./references#CD010292-bbs2-0027" title="NatelsonBH , VuD , MaoX , WeiduschatN , TogoF , Lange G et al. Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:1211-9. ">Natelson 2015</a>; <a href="./references#CD010292-bbs2-0030" title="NCT00793520. Effect of milnacipran on pain processing and functional magnetic resonance imaging (fMRI) activation patterns in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00793520&amp;Search=Search First posted: November 19,2008. ">NCT00793520</a>; <a href="./references#CD010292-bbs2-0031" title="NCT01108731. The effect of milnacipran in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01108731&amp;Search=Search First posted: April 22, 2010. ">NCT01108731</a>; <a href="./references#CD010292-bbs2-0033" title="NCT01234675. The effects of milnacipran on sleep disturbance in fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01234675&amp;Search=Search First posted: November 4, 2010. ">NCT01234675</a>); 11 studies had no control group (<a href="./references#CD010292-bbs2-0021" title="BrancoJC , CherinP , MontagneA , BouroubiA , Multinational Coordinator Study Group. Long term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology2011;38:1403-12. ">Branco 2011</a>; <a href="./references#CD010292-bbs2-0022" title="ChappellAS , LittlejohnG , KajdaszDK , ScheinbergM , D’SouzaDN , MoldofskyH . A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clinical Journal of Pain2009;25:365-75. ">Chappell 2009b</a>; <a href="./references#CD010292-bbs2-0023" title="DwightMM , ArnoldLM , O’BrienH , MetzgerR , Morris-ParkE , Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics1998;39:14-7. ">Dwight 1998</a>;<a href="./references#CD010292-bbs2-0024" title="GoldenbergDL , ClauwDJ , PalmerRH , MeaseP , ChenW , GendreauRM . Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Medicine2010;11:180-94. ">Goldenberg 2010</a>; <a href="./references#CD010292-bbs2-0025" title="HsiaoMC . Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine. Primary Care Companion to the Journal of Clinical Psychiatry2007;9:398. ">Hsiao 2007</a>; <a href="./references#CD010292-bbs2-0026" title="MeasePJ , RussellIJ , KajdaszDK , WiltseCG , DetkeMJ , Wohlreich MM et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism2010;39:354-64. ">Mease 2010</a>; <a href="./references#CD010292-bbs2-0029" title="AllenR , SharmaU , BarlasS . Clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome. Clinical Pharmacology in Drug Development2017;6:224-33. NCT00725101. Fibromyalgia health outcome study on cost of treatments (REFLECTIONS). clinicaltrials.gov/ct2/results?term=NCT00725101&amp;Search=Search First Posted: July 30, 2008. ">NCT00725101</a>; <a href="./references#CD010292-bbs2-0034" title="NCT01294059. Effects of milnacipran on widespread mechanical and thermal hyperalgesia of fibromyalgia patients. clinicaltrials.gov/ct2/results?term=NCT01294059&amp;Search=Search First posted: February 11, 2011. ">NCT01294059</a>; <a href="./references#CD010292-bbs2-0035" title="NCT01331109. Long-term safety and efficacy study of milnacipran in pediatric patients with primary fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01331109&amp;Search=Search First posted: April 7, 2011. ">NCT01331109</a>; <a href="./references#CD010292-bbs2-0036" title="NCT01621191. An extension study of duloxetine in fibromyalgia (extension of F1J-JE-HMGZ, NCT01552057). clinicaltrials.gov/ct2/results?term=NCT01621191&amp;Search=Search First posted: June 12, 2012. ">NCT01621191</a>; <a href="./references#CD010292-bbs2-0038" title="SayarK , AksuG , AkI , TosunM . Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy2003;37:1561-5. ">Sayar 2003</a>); two studies did not include outcomes of efficacy, which were preconditions to be included into our review (<a href="./references#CD010292-bbs2-0032" title="NCT01173055. A study to evaluate the effects of milnacipran on pain processing and functional MRI in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01173055&amp;Search=Search First posted: July 30, 2010. ">NCT01173055</a>; <a href="./references#CD010292-bbs2-0039" title="TrugmanJM , PalmerRH , MaY . Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Current Medical Research &amp; Opinion2014;30:589-97. ">Trugman 2014</a>); one study combined milnacipran with education or psychological therapies (<a href="./references#CD010292-bbs2-0020" title="AngDC , JensenMP , SteinerJL , HilligossJ , GracelyRH , SahaC . Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clinical Journal of Pain2013;29:747-54. ">Ang 2013</a>); one study duration was shorter than four weeks (<a href="./references#CD010292-bbs2-0037" title="SaxePA , ArnoldLM , PalmerRH , GendreauRM , ChenW . Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Current Medical Research and Opinion2012;28(5):815-21. ">Saxe 2012</a>); one study was only published as an abstract (<a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>); and for one study the study results were incompletely reported and not suited for quantitative analysis (<a href="./references#CD010292-bbs2-0028" title="NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&amp;cond=fibromyalgia&amp;rank=4 First posted: August 29, 2006. ">NCT00369343</a>). </p> </section> <section id="CD010292-sec-0070"> <h4 class="title">Studies awaiting classification</h4> <p>We found one study with duloxetine 60 mg a day whose results were not reported (<a href="./references#CD010292-bbs2-0042" title="NCT01268631. Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile? (MTF). clinicaltrials.gov/ct2/results?term=NCT01268631&amp;Search=Search First posted: December 31, 2010. ">NCT01268631</a>). The recruitment status of another study was unknown (<a href="./references#CD010292-bbs2-0042" title="NCT01268631. Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile? (MTF). clinicaltrials.gov/ct2/results?term=NCT01268631&amp;Search=Search First posted: December 31, 2010. ">NCT01268631</a>). </p> </section> </section> <section id="CD010292-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>In general, the risks of bias of included studies differed between the studies (see <a href="#CD010292-fig-0002">Figure 2</a> and <a href="#CD010292-fig-0003">Figure 3</a> for 'Risk of bias' summary and graph). Detailed information regarding 'Risk of bias' assessments of every study are given in the <a href="./references#CD010292-sec-0196" title="">Characteristics of included studies</a> table. Seven studies met the predefined criteria of high quality for methodology (<a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>; <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>), seven studies of moderate quality for methodology (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>) and four studies of low quality for methodology (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). The assessment is based on the reports in the publications. We did not request missing details of methods in the update of the review as we did in the first review because we did not get responses to some of our requests in the first version of the review. </p> <div class="figure" id="CD010292-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010292-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010292-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010292-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010292-sec-0072"> <h4 class="title">Allocation</h4> <p>Random sequence generation was adequately described and therefore all studies were at low risk of bias except <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>, <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a> which did not adequately describe it (unclear risk of bias). </p> <p>Allocation concealment was adequately described and therefore all studies were at low risk of bias except <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a> and <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>, which did not adequately describe it (unclear risk of bias). </p> </section> <section id="CD010292-sec-0073"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was adequately described in all studies except <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a> and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>, which did not adequately describe it (unclear risk of bias). </p> </section> <section id="CD010292-sec-0074"> <h4 class="title">Blinding (detection bias)</h4> <p>Blinding of outcome assessors was adequately described in all studies except <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a> and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>, which did not adequately describe it (unclear risk of bias). </p> </section> <section id="CD010292-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Most outcomes of the study of <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a> were based on analysis of observed cases that were provided on request (high risk of bias). <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a> and <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a> also performed completer analysis (high risk of bias). Only <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a> provided analysis by the baseline observation carried forward method. The remaining studies imputed missing data by baseline or last observation carried forward and therefore we judged them to be at unclear risk of bias. </p> </section> <section id="CD010292-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Only <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a> and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a> reported or provided on request all data of interest for this review if outlined in the protocol, and we judged them to be at low risk of bias. We judged the remaining studies to be at high risk of bias. </p> </section> <section id="CD010292-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010292-sec-0078"> <h5 class="title">Group similarity at baseline</h5> <p>No significant differences in demographic and clinical variables between the study groups (low risk of bias) could be detected in the studies included except in <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a> and <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a> (high risk of bias). </p> </section> <section id="CD010292-sec-0079"> <h5 class="title">Sample size bias</h5> <p>The sample size was of a low risk of bias only in <a href="./references#CD010292-bbs2-0003" title="ArnoldLM , ClauwD , WangF , AhlJ , GaynorPJ , WohlreichMM . Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2010;37(12):2578-86. MohsR , MeaseP , ArnoldLM , WangF , AhlJ , Gaynor PJ et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine2012;74:628-34. ">Arnold 2010a</a>; <a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; <a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>; <a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a> and <a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>. Six studies had a high risk of bias (<a href="./references#CD010292-bbs2-0006" title="BatemanL , PalmerRH , TrugmanJM , LinY . Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research2013;6:311-8. ">Bateman 2013</a>; <a href="./references#CD010292-bbs2-0011" title="LeombruniP , MiniottiM , ColonnaF , SicaC , CastelliL , Bruzzone M et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology2015;33:S82-5. ">Leombruni 2015</a>; <a href="./references#CD010292-bbs2-0012" title="MattheyA , CedraschiC , PiguetV , BessonM , ChabertJ , Daali Y et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician2013;16:E553-62. ">Matthey 2013</a>; <a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>; <a href="./references#CD010292-bbs2-0017" title="StaudR , LucasYE , PriceDD , RobinsonME . Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain2015;16:750-9. ">Staud 2015</a>; <a href="./references#CD010292-bbs2-0018" title="GendreauRM , ThornMD , GendreauJF , KranzlerJD , RibeiroS , Gracely RH et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology2005;32(10):1975-85. VittonO , GendreauM , GendreauJ , KranzlerJ , RaoSG . A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology2004;19(Suppl 1):S27-35. ">Vitton 2004</a>) and seven studies an unclear risk of bias (<a href="./references#CD010292-bbs2-0001" title="ArnoldLM , LuY , CroffordLJ , WohlreichM , DetkeMJ , Iyengar S et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism2004;50(9):2974-84. ">Arnold 2004</a>; <a href="./references#CD010292-bbs2-0002" title="ArnoldLM , RosenA , PritchettYL , D'SouzaDN , GoldsteinDJ , Iyengar S et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain2005;119(1-3):5-15. ">Arnold 2005</a>; <a href="./references#CD010292-bbs2-0005" title="ArnoldLM , ZhangS , PangalloBA . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain2012;28:775-81. ">Arnold 2012a</a>; <a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>; <a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>; <a href="./references#CD010292-bbs2-0014" title="MurakamiM , OsadaK , MizunoH , OchiaiT , NishiokaK . A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research &amp; Therapy2015;17:224. ">Murakami 2015</a>; <a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). </p> </section> </section> </section> <section id="CD010292-sec-0080"> <h3 class="title" id="CD010292-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD010292-tbl-0001"><b>Summary of findings 1</b> Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</a> </p> <section id="CD010292-sec-0081"> <h4 class="title">All SNRIs (desvenlafaxine, duloxetine, milnacipran) versus placebo, studies with parallel and cross‐over design </h4> <section id="CD010292-sec-0082"> <h5 class="title">Primary outcomes</h5> <section id="CD010292-sec-0083"> <h6 class="title">Self‐reported pain relief of 50% or greater</h6> <p>We entered 15 studies with 6918 participants into an analysis of the RD of participant‐reported pain relief of 50% or greater. For this outcome, 1274 of 4104 (31.0%) participants with duloxetine and milnacipran and 591 out of 2814 (21.0%) participants in the placebo group reported pain relief of 50% or greater. The RD was 0.09 (95% CI 0.07 to 0.11) (see <a href="./references#CD010292-fig-0004" title="">Analysis 1.1</a>). NNTB was 11 (95% CI 9 to 14) (P value &lt; 0.0001). According to the predefined categories there was no clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias (see <a href="./full#CD010292-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD010292-sec-0084"> <h6 class="title">Patient global impression to be much or very much improved</h6> <p>We entered six studies with 2918 participants into an analysis of patient global impression much or very much improved. There were 888 participants out of 1710 (51.9%) with duloxetine and milnacipran and 354 of 1208 (29.3%) participants in the placebo group reported to be much or very much improved. The RD was 0.19 (95% CI 0.12 to 0.26) (see <a href="./references#CD010292-fig-0005" title="">Analysis 1.2</a>). NNTB was 5 (95% CI 4 to 8) (P value &lt; 0.0001). According to the predefined categories there was a clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0085"> <h6 class="title">Tolerability (withdrawals due to adverse events)</h6> <p>We entered 15 studies, with 7029 participants, into an analysis of withdrawals due to adverse events. Out of 4166 participants with desvenlafaxine, duloxetine and milnacipran, 794 (19.1%) dropped out due to adverse events and 292 participants out of 2863 (10.2%) dropped out in the placebo group. The RD was 0.07 (95% CI 0.04 to 0.10). The NNTH with desvenlafaxine, duloxetine and milnacipran was 14 (95% CI 10 to 25) (P value &lt; 0.0001) (see <a href="./references#CD010292-fig-0006" title="">Analysis 1.3</a>). According to the predefined categories there was no clinically meaningful harm with desvenlafaxine, duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0086"> <h6 class="title">Safety (serious adverse events)</h6> <p>We entered 13 studies, with 6732 participants, into an analysis of serious adverse events. In 73 out of 4022 (1.8%) participants with desvenlafaxine, duloxetine and milnacipran and in 58 out of 2710 (2.1%) in the placebo group an adverse event was noted. The RD was ‐0.00 (95% CI ‐0.01 to 0.00) (P value 0.90) (<a href="./references#CD010292-fig-0007" title="">Analysis 1.4</a>). The quality of evidence was very low, downgraded due to indirectness, imprecision and publication bias. </p> </section> </section> <section id="CD010292-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD010292-sec-0088"> <h6 class="title">Self‐reported fatigue</h6> <p>We entered 12 studies with 6168 participants into an analysis of the effects of desvenlafaxine, duloxetine and milnacipran on fatigue reduction. The SMD was ‐0.13 (95% CI ‐0.18 to ‐0.08) (P value &lt; 0.001). Based on Cohen's categories, the effect on fatigue of SNRIs versus placebo was not substantial (<a href="./references#CD010292-fig-0008" title="">Analysis 1.5</a>). The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0089"> <h6 class="title">Self‐reported sleep problems</h6> <p>We entered eight studies, with 4547 participants, into an analysis of the effects of duloxetine and milnacipran on reduction of sleep disturbances. The overall effect on sleep disturbances was not significant (P value = 0.11) (see <a href="./references#CD010292-fig-0009" title="">Analysis 1.6</a>). The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0090"> <h6 class="title">Self‐reported health‐related quality of life</h6> <p>We entered 14 studies, with 6861 participants, into an analysis of the effects of duloxetine and milnacipran on health‐related quality of life. SMD was ‐0.20 (95% CI ‐0.25 to ‐0.15) (P value &lt; 0.0001). Based on Cohen's categories the effect on disease‐related quality of life of SNRIs versus placebo was not substantial (<a href="./references#CD010292-fig-0010" title="">Analysis 1.7</a>). The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0091"> <h6 class="title">Self‐reported pain relief of 30% or greater</h6> <p>We entered 15 studies, with 6924 participants, into an analysis of the RD of participant‐reported pain relief of 30% or greater. There were 1653 out of 4105 participants (40.3%) with duloxetine and milnacipran and 888 out of 2819 (31.5%) participants in the placebo group who reported pain relief of 30% and more. The RD was 0.10 (95% CI 0.08 to 0.12). NNTB was 10 (95% CI 8 to 12) (P value &lt; 0.0001) (<a href="./references#CD010292-fig-0011" title="">Analysis 1.8</a>). According to the predefined categories there was a clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0092"> <h6 class="title">Self‐reported pain intensity</h6> <p>We entered 16 studies, with 7014 participants, into an analysis of the effects of desvenlafaxine, duloxetine and milnacipran on pain intensity reduction.The SMD was ‐0.22 (95% CI ‐0.27 to ‐0.17) (P value &lt; 0.0001). According to Cohen's categories the effect on pain of desvenlafaxine, duloxetine and milnacipran compared to placebo was small (<a href="./references#CD010292-fig-0012" title="">Analysis 1.9</a>). According to the predefined categories there was a clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0093"> <h6 class="title">Self‐reported depression</h6> <p>We entered 14 studies, with 6478 participants into an analysis of the effects of duloxetine and milnacipran on depression reduction. One study reported only the outcomes of one of three dosage groups (<a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). SMD was ‐0.16 (95% CI ‐0.21 to ‐0.11) (P value &lt; 0.0001) (<a href="./references#CD010292-fig-0013" title="">Analysis 1.10</a>). Based on Cohen's categories, the effect on depression of duloxetine and milnacipran versus placebo was not substantial. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0094"> <h6 class="title">Self‐reported anxiety</h6> <p>We entered 9 studies, with 3533 participants, into an analysis of the effects of duloxetine and milnacipranon anxiety reduction. The overall effect on anxiety was not significant (P value = 0.21) (<a href="./references#CD010292-fig-0014" title="">Analysis 1.11</a>). The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0095"> <h6 class="title">Self‐reported disability</h6> <p>We entered 13 studies, with 6789 participants into an analysis of the effects of duloxetine and milnacipran on disability reduction. SMD was ‐0.21 (95% CI ‐0.26 to ‐0.16) (P value &lt; 0.0001). Based on Cohen's categories the effect on disability of duloxetine and milnacipran versus placebo was small (<a href="./references#CD010292-fig-0015" title="">Analysis 1.12</a>). According to the predefined categories there was a clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0096"> <h6 class="title">Self‐reported sexual function</h6> <p>One study with 100 participants assessed the effects of milnacipran on sexual function. There was no difference between milnacipran and placebo on sexual function (P value = 0.59). The quality of evidence was very low, downgraded due to indirectness, imprecision and publication bias. </p> </section> <section id="CD010292-sec-0097"> <h6 class="title">Self‐reported cognitive disturbances</h6> <p>We entered eight studies, with 5444 participants, into an analysis of the effects of duloxetine and milnacipran on cognitive disturbances. The overall effect on 'fibro fog' was significant (P value &lt; 0.0001). SMD was ‐0.16 (95% CI ‐0.21 to ‐0.10). Based on Cohen's categories, the effect on cognitive disturbances of duloxetine and milnacipran versus placebo was not substantial (<a href="./references#CD010292-fig-0016" title="">Analysis 1.13</a>). The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0098"> <h6 class="title">Tenderness</h6> <p>We entered five studies, with 1444 participants, which performed tender point pain threshold measurement. Duloxetine and milnacipran were superior to placebo in raising the tender point pain threshold (P value = 0.0007), suggesting less tenderness. SMD was ‐0.21 (95% CI ‐0.33 to ‐0.09). Based on Cohen's categories the effect on tenderness of duloxetine and milnacipran versus placebo was small (<a href="./references#CD010292-fig-0017" title="">Analysis 1.14</a>). According to the predefined categories there was a clinically meaningful benefit with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0099"> <h6 class="title">Dropout due to lack of efficacy</h6> <p>We entered 14 studies, with 6924 participants into an analysis of withdrawals due to lack of efficacy. Out of 4082 participants with desvenlafaxine, duloxetine and milnacipran, 264 (6.5%) dropped out due to lack of efficacy and 258 out of 2842 (9.1%) dropped out in the placebo group. The RD was ‐0.03 (95% CI ‐0.04 to ‐0.02). The number of participants needed to prevent an additional unwanted outcome (NNTp) with desvenlafaxine, duloxetine and milnaciprans was 33 (95% CI 25 to 50) (P value &lt; 0.0001) (see <a href="./references#CD010292-fig-0018" title="">Analysis 1.15</a>). According to the predefined categories there was no clinically meaningful benefit by desvenlafaxine, duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0100"> <h6 class="title">Specific adverse events</h6> <section id="CD010292-sec-0101"> <p><b>Nausea</b></p> <p>We entered 12 studies, with 6606 participants, into an analysis of nausea as an adverse event. Out of 3918 participants with desvenlafaxine, duloxetine and milnacipran, 1253 (32.0 %) reported nausea and 382 out of 2688 participants reported nausea (14.2%) in the placebo group. The RD was 0.16 (95% CI 0.14 to 0.19). The NNTH with desvenlafaxine, duloxetine and milnacipran was 6 (95% CI 5 to 7) (P value &lt; 0.0001) (see <a href="./references#CD010292-fig-0019" title="">Analysis 1.16</a>). According to the predefined categories there was a clinically meaningful harm with desvenlafaxine, duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0102"> <p><b>Somnolence</b></p> <p>We entered seven studies, with 2514 participants, into an analysis of somnolence as an adverse event. Out of 1426 participants with duloxetine and milnacipran, 155 (10.9%) reported somnolence and 51 participants out of 1088 (4.7%) reported somnolence in the placebo group. The RD was 0.05 (95% CI 0.02 to 0.08). The NNTH with SNRIs was 20 (95% CI 12 to 50) (P value = 0.0004) (see <a href="./references#CD010292-fig-0020" title="">Analysis 1.17</a>). According to the predefined categories there was no clinically meaningful harm with duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> <section id="CD010292-sec-0103"> <p><b>Insomnia</b></p> <p>We entered nine studies, with 5387 participants, into an analysis of insomnia as an adverse event. Out of 3119 participants with desvenlafaxine, duloxetine and milnacipran, 298 (9.6 %) reported insomnia and 132 participants out of 2268 (5.8%) reported insomnia in the placebo group. The RD was 0.03 (95% CI 0.01 to 0.04) (P value &lt; 0.0001). The NNTH with desvenlafaxine, duloxetine and milnacipran was 33 (95% CI 25 to 100) (see <a href="./references#CD010292-fig-0021" title="">Analysis 1.18</a>). According to the predefined categories there was no clinically meaningful harm with desvenlafaxine, duloxetine and milnacipran. The quality of evidence was low, downgraded due to indirectness and publication bias. </p> </section> </section> </section> </section> <section id="CD010292-sec-0104"> <h4 class="title">All SNRIs versus placebo, studies with enriched enrolment randomized withdrawal design</h4> <p>We downgraded the quality of evidence by one level each to very low because of limitations of study design, indirectness and imprecision for all outcomes. We present a qualitative analysis of the data because there was only one study with 151 participants examining milnacipran available (<a href="./references#CD010292-bbs2-0010" title="ClauwDJ , MeasePJ , PalmerRH , TrugmanJM , WangY . Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research &amp; Therapy2013;15:R88. MeasePJ , ClauwDJ , TrugmanJM , PalmerRH , WangY . Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research2014;7:679-87. ">Clauw 2013</a>). </p> <section id="CD010292-sec-0105"> <h5 class="title">Primary outcomes</h5> <section id="CD010292-sec-0106"> <h6 class="title">Loss of therapeutic response for self‐reported pain relief</h6> <p>There were 35 of 100 (35%) participants in the milnacipran group and 32 of 51 (62.7%) participants in the placebo group who reported a loss of therapeutic response (P value 0.0008). </p> </section> <section id="CD010292-sec-0107"> <h6 class="title">Loss of therapeutic response for patient's global impression to be much or very much improved </h6> <p>There were 22 of 100 participants (22%) in the milnacipran and 25 of 51 (49.0%) participants in the placebo group reported to be much or very much worse (P value 0.0009). </p> </section> <section id="CD010292-sec-0108"> <h6 class="title">Tolerability (withdrawals due to adverse events)</h6> <p>Two of 100 (2%) participants in the milnacipran and 0 of 51 (0%) participants in the placebo group dropped out due to adverse events (P value 0.33). </p> </section> <section id="CD010292-sec-0109"> <h6 class="title">Safety (serious adverse events)</h6> <p>One of 100 (1%) participants in the milnacipran and 0 of 51 (0%) participants in the placebo group experienced a serious adverse event (P value 0.58). </p> </section> </section> <section id="CD010292-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD010292-sec-0111"> <h6 class="title">Self‐reported fatigue: Loss of therapeutic response</h6> <p>There were 36 of 100 participants (36%) in the milnacipran and 20 of 51 participants (39.2%) in the placebo group who reported a loss of therapeutic response of reduction of fatigue (P value 0.70). </p> </section> <section id="CD010292-sec-0112"> <h6 class="title">Self‐reported sleep problems: Loss of therapeutic response</h6> <p>This outcome was not assessed by the study.</p> </section> <section id="CD010292-sec-0113"> <h6 class="title">Self‐reported health‐related quality of life: Loss of therapeutic response</h6> <p>This outcome was not reported by the study.</p> </section> <section id="CD010292-sec-0114"> <h6 class="title">Self‐reported depression: Loss of therapeutic response</h6> <p>This outcome was not reported by the study.</p> </section> <section id="CD010292-sec-0115"> <h6 class="title">Self‐reported anxiety: Loss of therapeutic response</h6> <p>This outcome was not reported by the study.</p> </section> <section id="CD010292-sec-0116"> <h6 class="title">Self‐reported disability: Loss of therapeutic response</h6> <p>There were 47 of 100 (47%) participants in the milnacipran and 26 of 51 (51%) participants in the placebo group who reported a loss of therapeutic response of reduction of self‐reported disability (P value 0.82). </p> </section> <section id="CD010292-sec-0117"> <h6 class="title">Self‐reported sexual function: Loss of therapeutic response</h6> <p>This outcome was not assessed by the study.</p> </section> <section id="CD010292-sec-0118"> <h6 class="title">Self‐reported cognitive disturbances: Loss of therapeutic response</h6> <p>This outcome was not assessed by the study.</p> </section> <section id="CD010292-sec-0119"> <h6 class="title">Tenderness: Loss of therapeutic response</h6> <p>This outcome was not assessed by the study.</p> </section> <section id="CD010292-sec-0120"> <h6 class="title">Dropout due to lack of efficacy</h6> <p>This outcome was not reported sufficiently for meta‐analysis.</p> </section> <section id="CD010292-sec-0121"> <h6 class="title">Specific adverse events</h6> <section id="CD010292-sec-0122"> <p><b>Nausea</b></p> <p>Four of 100 (4%) participants with milnacipran and 1 of 50 (2%) participants with placebo reported nausea as an adverse event (P value 0.52). </p> </section> <section id="CD010292-sec-0123"> <p><b>Somnolence</b></p> <p>This outcome was not reported by the study.</p> </section> <section id="CD010292-sec-0124"> <p><b>Insomnia</b></p> <p>This outcome was not reported by the study.</p> </section> </section> </section> </section> <section id="CD010292-sec-0125"> <h4 class="title">All SNRIs versus other active drugs</h4> <p>We present a qualitative analysis of the data because we analysed only two studies with fewer than 200 participants for this comparison. We downgraded the quality of evidence by one level each because of limitations of study design, indirectness and imprecision to very low for each outcome. </p> <section id="CD010292-sec-0126"> <h5 class="title">Primary outcomes</h5> <section id="CD010292-sec-0127"> <h6 class="title">Self‐reported pain relief of 50% or greater</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0128"> <h6 class="title">Patient global impression to be much or very much improved</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0129"> <h6 class="title">Tolerability (withdrawals due to adverse events)</h6> <p>Eight of 28 participants (28.6%) with duloxetine and 0 of 56 (0%) participants with L‐carnitine withdrew due to side effects (P value 0.008). None of 42 (0%) participants with desvenlafaxine and six of 43 (14.0%) participants with pregabalin dropped out due to side effects (P value 0.02). </p> </section> <section id="CD010292-sec-0130"> <h6 class="title">Safety (serious adverse events)</h6> <p>No serious adverse event was reported in the study with duloxetine versus L‐carnitine. A serious adverse event was noted in one of the 42 (2.4%) participants with desvenlafaxine and in 1 of 43 (2.3%) participants with pregabalin (P value 0.99). </p> </section> </section> <section id="CD010292-sec-0131"> <h5 class="title">Secondary outcomes</h5> <section id="CD010292-sec-0132"> <h6 class="title">Self‐reported fatigue</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0133"> <h6 class="title">Self‐reported sleep problems</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0134"> <h6 class="title">Self‐reported health‐related quality of life</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0135"> <h6 class="title">Self‐reported pain relief of 30% or greater</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0136"> <h6 class="title">Self‐reported pain intensity</h6> <p>There was no statistically significant difference between duloxetine and L‐carnitine (P value 0.87). </p> </section> <section id="CD010292-sec-0137"> <h6 class="title">Self‐reported depression</h6> <p>There was no statistically significant difference between duloxetine and L‐carnitine (P value 0.33). </p> </section> <section id="CD010292-sec-0138"> <h6 class="title">Self‐reported anxiety</h6> <p>There was no statistically significant difference between duloxetine and L‐carnitine (P value 0.76). </p> </section> <section id="CD010292-sec-0139"> <h6 class="title">Self‐reported disability</h6> <p>There was no statistically significant difference between duloxetine and L‐carnitine (P value 0.42). </p> </section> <section id="CD010292-sec-0140"> <h6 class="title">Self‐reported sexual function</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0141"> <h6 class="title">Self‐reported cognitive disturbances</h6> <p>This outcome was not reported by the studies analysed.</p> </section> <section id="CD010292-sec-0142"> <h6 class="title">Tenderness</h6> <p>This outcome was not reported by the studies analysed.</p> <p><b>Dropout due to lack of efficacy</b> </p> <p>Three of 42 (7.1%) participants with desvenlafaxine and none of 43 participants with pregabalin dropped out due to lack of efficacy (P value 0.09). No participant with duloxetine and L‐carnitine dropped out due to lack of efficacy. </p> </section> <section id="CD010292-sec-0143"> <h6 class="title">Specific adverse events</h6> <section id="CD010292-sec-0144"> <p><b>Nausea</b></p> <p>Six of 42 (14.3%) participants with desvenlafaxine and three of 43 (7.0%) participants with pregabalin reported nausea as an adverse event (P value 0.15). </p> </section> <section id="CD010292-sec-0145"> <p><b>Somnolence</b></p> <p>Two of 42 (4.8%) participants with desvenlafaxine and six of 43 (13.6%) participants with pregabalin reported somnolence as an adverse event (P value 0.33). </p> </section> <section id="CD010292-sec-0146"> <p><b>Insomnia</b></p> <p>One of 42 (2.4%) participants with desvenlafaxine and none of 43 (0%) participants with pregabalin reported insomnia as an adverse event (P value 0.31). </p> </section> </section> </section> </section> <section id="CD010292-sec-0147"> <h4 class="title">Heterogeneity</h4> <p>I² statistic of all comparisons was less than 25% except for the outcome 'withdrawal due to adverse events' in the comparison SNRIs versus placebo (60%) and the outcome 'withdrawal due to adverse events' in the comparison SNRIs versus other active drugs (95%). </p> </section> <section id="CD010292-sec-0148"> <h4 class="title">Publication bias</h4> <p>Studies with 1459 participants with a null effect on patient global impression to be much or very much improved would have been required to make the result clinically irrelevant (NNTB of 10 or higher). </p> </section> <section id="CD010292-sec-0149"> <h4 class="title">Subgroup analysis</h4> <section id="CD010292-sec-0150"> <h5 class="title">Duloxetine and milnacipran</h5> <p>There was no difference between duloxetine and milnacipran in the rates of pain relief of 50% or greater (P value 0.53) (see <a href="./references#CD010292-fig-0004" title="">Analysis 1.1</a>), in the reduction of fatigue (P value 0.73) (see <a href="./references#CD010292-fig-0008" title="">Analysis 1.5</a>) and in improvement of health‐related quality of life (P value 0.56) (see <a href="./references#CD010292-fig-0010" title="">Analysis 1.7</a>). Duloxetine was superior to milnacipran in the number of participants who reported to be much or very much improved (P value &lt; 0.0001) (see <a href="./references#CD010292-fig-0005" title="">Analysis 1.2</a>) and in reducing sleep problems (P value 0.0006) (see <a href="./references#CD010292-fig-0009" title="">Analysis 1.6</a>). The dropout rate due to adverse events in milnacipran studies was higher than in duloxetine studies (P value 0.0007) (see <a href="./references#CD010292-fig-0006" title="">Analysis 1.3</a>). There was no difference between duloxetine and milnacipran in the frequency of serious adverse events (P value 0.90) (see <a href="./references#CD010292-fig-0007" title="">Analysis 1.4</a>). </p> <p>There was no difference between duloxetine and milnacipran in the rates of pain relief of 30% and greater (P value 0.65) (see <a href="./references#CD010292-fig-0011" title="">Analysis 1.8</a>) and dropout rates due to lack of efficacy (P value 0.22) (see <a href="./references#CD010292-fig-0018" title="">Analysis 1.15</a>). There was no difference in reduction of mean pain intensity between duloxetine and milnacipran (P value 0.10) (see <a href="./references#CD010292-fig-0012" title="">Analysis 1.9</a>). Duloxetine was superior to milnacipran in reducing depression (P value 0.007) (see <a href="./references#CD010292-fig-0013" title="">Analysis 1.10</a>), disability (P value 0.01) (see <a href="./references#CD010292-fig-0015" title="">Analysis 1.12</a>) and cognitive disturbances (P value 0.02) (see <a href="./references#CD010292-fig-0016" title="">Analysis 1.13</a>). There was no difference between duloxetine and milnacipran in reducing anxiety (P value 0.74) (see <a href="./references#CD010292-fig-0014" title="">Analysis 1.11</a>) and tenderness (P value 0.12) (see <a href="./references#CD010292-fig-0017" title="">Analysis 1.14</a>). There was no difference between duloxetine and milnacipran in the frequency of nausea (P value 0.12) (see <a href="./references#CD010292-fig-0019" title="">Analysis 1.16</a>) and insomnia (P value 0.39) (see <a href="./references#CD010292-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD010292-sec-0151"> <h5 class="title">Studies with and without European participants</h5> <p>The RD of pain relief of 50% and more and of withdrawals due to adverse events did not differ between studies without European participants than with European participants (see Additional <a href="#CD010292-tbl-0002">Table 1</a>). </p> <div class="table" id="CD010292-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis. Efficacy and safety of SNRIs in studies with North American and European participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number</b> </p> <p><b>of</b> </p> <p><b>participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect size</b> </p> <p><b>RD (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test for</b> </p> <p><b>overall</b> </p> <p><b>effect</b> </p> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity</b> </p> <p><b>I²</b> (<b>%</b>) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test of interaction:</b> </p> <p><b>effect estimate and P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported pain relief 50% or greater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Z = 0.78; P = 0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only North American participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3935 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.08 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only European participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.01 to 0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Z = 1.14; P = 0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only North American participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3935 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (0.04 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only European participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.08 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>RD</b> : risk difference; <b>SNRIs</b>: serotonin and noradrenaline reuptake inhibitors </p> </div> </div> </section> </section> <section id="CD010292-sec-0152"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct the intended sensitivity analyses (different statistical models applied, diagnostic criteria used in the trial, according to the presence or absence of any mental or psychiatric disorder, presence or absence of any concomitant systemic disease), because the studies did not differ in these characteristics. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010292-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010292-sec-0153"></div> <section id="CD010292-sec-0154"> <h3 class="title" id="CD010292-sec-0154">Summary of main results</h3> <p>The SNRIs duloxetine and milnacipran did not show a clinically relevant benefit compared to placebo in participant‐reported pain relief of 50% or greater. The SNRIs duloxetine and milnacipran showed a clinically relevant benefit compared to placebo in participant‐reported pain relief of 30% or greater and in increased patient‐perceived global improvement. The SNRIs duloxetine and milnacipran had a clinically relevant benefit compared to placebo in reducing mean pain intensity, disability and tenderness. The effect of duloxetine and milnacipran compared to placebo in reducing fatigue, depression, limitations of health‐related quality of life and cognitive disturbances was not clinically relevant. There were no differences between duloxetine or milnacipran and placebo in reducing sleep problems and anxiety. The dropout rate due to adverse events with duloxetine or milnacipran did not show a clinically relevant difference to placebo. There were no differences in the frequency of serious adverse events between duloxetine or milnacipran and placebo. Desvenlafaxine was not superior to placebo in mean pain intensity reduction. </p> </section> <section id="CD010292-sec-0155"> <h3 class="title" id="CD010292-sec-0155">Overall completeness and applicability of evidence</h3> <p>We are confident that we did not miss studies of SNRIs duloxetine and milnacipran, because all trials with these drugs had been registered with the application of an approval for fibromyalgia management by regulatory agencies. We cannot rule out the possibility that negative study results with other SNRIs have not been published or have been missed by our search strategy. We identified one study investigating desvenlafaxine that had been terminated prior to completion. The data available did not suggest any therapeutic effect (<a href="./references#CD010292-bbs2-0028" title="NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&amp;cond=fibromyalgia&amp;rank=4 First posted: August 29, 2006. ">NCT00369343</a>). </p> <p>The applicability (external validity) of evidence is very limited for the following reasons. </p> <p> <ul id="CD010292-list-0011"> <li> <p>The studies were performed in research centers and not in routine clinical care. It is known that the efficacy of drug therapies is higher in the context of RCTs than in routine clinical care (<a href="./references#CD010292-bbs2-0115" title="RoutmanJS , WilligJH , WestfallAO , AbromsSR , VarshneyM , Adusumilli S et al. Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clinical Infectious Diseases2010;15(4):574-84.">Routman 2010</a>). </p> </li> <li> <p>The substantial placebo and nocebo response rates seen across all of the SNRI trials impede the appraisal of the efficacy and tolerability of SNRIs in fibromyalgia. However, the high degree of placebo and nocebo rates that have been seen with SNRIs have also been observed in all fibromyalgia drug trials (<a href="./references#CD010292-bbs2-0080" title="HäuserW , Bartram-WunnE , BartramC , TölleTR . Placebo responders in randomized controlled drug trials of fibromyalgia syndrome: systematic review and meta-analysis. Schmerz2011;25:19-31.">Häuser 2011</a>; <a href="./references#CD010292-bbs2-0081" title="HäuserW , BartramC , Bartram-WunnE , TölleT . Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clinical Journal of Pain2012;28:437-51.">Häuser 2012</a>). </p> </li> <li> <p>The exclusion criteria were strict. Participants were not allowed to take some defined concomitant medications for their fibromyalgia symptoms. This excluded a large number of participants who were unwilling, or unable, to come off medications, such as other antidepressants and anticonvulsants. For this reason, participant selection in the RCTs was biased towards recruiting participants with less severe symptoms than are seen in the community (<a href="./references#CD010292-bbs2-0070" title="Fuller-ThomsonE , Nimigon-YoungJ , BrennenstuhlS . Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatology International2012;32(4):853-62.">Fuller‐Thomson 2012</a>). Participants with other medical disorders, such as inflammatory rheumatic diseases, which are frequently associated with fibromyalgia, were also excluded. The study results cannot be applied to people with so‐called secondary fibromyalgia (associated with inflammatory rheumatic diseases) (<a href="./references#CD010292-bbs2-0057" title="ClauwDJ , KatzP . The overlap between fibromyalgia and inflammatory rheumatic disease: when and why does it occur?Journal of Clinical Rheumatology1995;1:335-42.">Clauw 1995</a>). All except one of the studies with milnacipran excluded all potential participants with major mental disorders, while the studies with duloxetine excluded all participants with major mental disorders except for those with major depression and general anxiety disorder. The study results cannot be applied to people with fibromyalgia and concomitant psychiatric disease, except for the duloxetine studies that suggest efficacy in fibromyalgia with major depression and general anxiety disorder. </p> </li> <li> <p>The majority of the participants were middle‐aged women. The authors of the duloxetine studies provided a pooled subgroup analysis that demonstrated the efficacy of duloxetine in male participants (<a href="./references#CD010292-bbs2-0016" title="RussellIJ , MeasePJ , SmithTR , KajdaszDK , WohlreichMM , Detke MJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain2008;136(3):432-44. ">Russell 2008</a>). A similar analysis was not available for milnacipran. Neither of the pharmaceutical companies (Eli‐Lilly and Pierre Fabre/Forest Laboratories) presented a subgroup analysis of participants over 65 years of age. </p> </li> <li> <p>Only adult participants were included. Whether the study results can be applied to children or adolescents remains to be clarified. One study with milnacipran in adolescents with fibromyalgia was terminated early due to low enrolment (<a href="./references#CD010292-bbs2-0049" title="ArnoldLM , BatemanL , PalmerRH , LinY . Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatric Rheumatology Online Journal2015;13:27.">Arnold 2015</a>). </p> </li> <li> <p>Even if the review included studies with a duration of therapy of up to 27 weeks, the long‐term efficacy and safety of SNRIs in fibromyalgia cannot be assessed by the studies included. Long‐term, open‐label extension studies with duloxetine and milnacipran demonstrated a sustained symptom relief and tolerability in up to 20% of the participants who were enrolled in the RCT prior to the open‐label period (<a href="./references#CD010292-bbs2-0048" title="ArnoldLM , PalmerRH , MaY . A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clinical Journal of Pain2013;29:1021-8.">Arnold 2013</a>; <a href="./references#CD010292-bbs2-0021" title="BrancoJC , CherinP , MontagneA , BouroubiA , Multinational Coordinator Study Group. Long term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology2011;38:1403-12. ">Branco 2011</a>; <a href="./references#CD010292-bbs2-0026" title="MeasePJ , RussellIJ , KajdaszDK , WiltseCG , DetkeMJ , Wohlreich MM et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism2010;39:354-64. ">Mease 2010</a>; <a href="./references#CD010292-bbs2-0098" title="MeasePJ , FarmerMV , PalmerRH , GendreauRM , WangY . Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Therapeutic Advances in Musculoskeletal Diseases2013;5:113-26.">Mease 2013</a>, <a href="./references#CD010292-bbs2-0106" title="MurakamiM , OsadaK , IchibayashiH , MizunoH , OchiaiT , Ishida M et al. An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia. Modern Rheumatology2017;27:688-95.">Murakami 2017</a>). </p> </li> <li> <p>Even if the review included two RCTs that compared SNRIs with other active drugs, the definite importance of SNRIs compared to other drugs and non‐pharmacological therapies still needs to be determined. The trial comparing desvenlafaxine with pregabalin was terminated early after Wyeth, the manufacturer of desvenlafaxine, was acquired by Pfizer, the manufacturer of pregabalin. There was no difference between the two drugs in pain reduction (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). A network meta‐analysis did not find relevant differences between drugs (tricyclic antidepressants, SNRIs, SSRIs and pregabalin) and aerobic exercise and cognitive behavioral therapies in mean pain reduction and total dropout rates (<a href="./references#CD010292-bbs2-0109" title="NüeschE , HäuserW , BernardyK , BarthJ , JüniP . Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Annals of Rheumatic Diseases2013;72:955-62.">Nüesch 2013</a>). </p> </li> </ul> </p> </section> <section id="CD010292-sec-0156"> <h3 class="title" id="CD010292-sec-0156">Quality of the evidence</h3> <p>The quality of evidence ranks from low to very low across the different outcomes. The likelihood that the effect could be substantially different is high or very high. The main limiting factors, which were the reasons for a decrease in quality in all outcomes, were indirectness and publication bias. All of the reviewed studies had been sponsored by pharmaceutical companies. The quality of evidence of this review is based on the data presented in peer reviewed journals and some additional details that were provided on request by the pharmaceutical companies or principal investigators. However, not all data requested were provided. A selective non‐reporting of some negative study results on pain, sleep and anxiety, as well as non‐reporting of serious adverse events is possible. </p> </section> <section id="CD010292-sec-0157"> <h3 class="title" id="CD010292-sec-0157">Potential biases in the review process</h3> <p>We searched for unpublished studies with SNRIs, but we are not certain that we identified all other studies that might have been performed but not published. </p> <p>We might have overestimated the risk of bias of some studies that were added to this update and that did not report some details of methodology (e.g. randomization and blinding procedures). In contrast to the first version of this review we did not ask the study authors or the sponsors of the studies for the missing details. </p> <p>Nearly all studies selected statistical methods (last observation carried forward) that bias results towards exaggerating the efficacy of drugs (<a href="./references#CD010292-bbs2-0103" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , Wiffen P et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153:265-8.">Moore 2012</a>). </p> <p>The subgroup comparisons of duloxetine versus milnacipran for the outcomes patient global impression to be much or very much improved and of sleep problems were limited due to the small number of studies presenting results suitable for meta‐analysis (patient impression of change) or assessing the outcome (sleep problems). </p> <p>The influence of allowed co‐interventions (e.g. rescue medication) on positive effects and adverse events was unclear because type and dosage of co‐interventions were not clearly reported or controlled for. </p> <p>This systematic review update included 7903 participants. To capture rare and potentially severe adverse events a larger data set would have been necessary. For example, to capture an adverse event with a frequency of 1:100,000, 300,000 patients would need to be observed (<a href="./references#CD010292-bbs2-0045" title="AndersohnF , GarbeE . Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz2008;51:1135-44.">Andersohn 2008</a>). Rare complications of SNRIs include suicide (<a href="./references#CD010292-bbs2-0119" title="TaylorD , Lenox-SmithA , BradleyA . A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Therapeutic Advances in Psychopharmacology2013;3:151-61.">Taylor 2013</a>), severe liver injury (<a href="./references#CD010292-bbs2-0123" title="VoicanCS , CorrubleE , NaveauS , PerlemuterG . Antidepressant-induced liver injury: a review for clinicians. American Journal of Psychiatry2014;171:404-15.">Voican 2014</a>), hypertension (<a href="./references#CD010292-bbs2-0061" title="deToledo Ferraz AlvesTC , Guerra de AndradeA . Hypertension induced by regular doses of milnacipran: a case report. Pharmacopsychiatry2007;40:41-2.">de Toledo 2007</a>) and sexual dysfunction (<a href="./references#CD010292-bbs2-0074" title="HigginsA , NashM , LynchAM . Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthcare and Patient Safety2010;10:141-50.">Higgins 2010</a>). </p> <p>We were not able to perform individual participant data analyses because these data were not published or provided by the sponsors of the studies. Therefore we could not test if moderate or substantial pain reduction was associated with improvement of fatigue, function, sleep, depression, anxiety, ability to work, and general health status, as has been demonstrated for pregabalin in fibromyalgia (<a href="./references#CD010292-bbs2-0102" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149:360-4.">Moore 2010c</a>). The NNTB for substantial pain relief with duloxetine and milnacipran in our analysis was lower than for relief of sleep problems and fatigue. In addition, sleep problems are a common side effect of SNRIs (<a href="./references#CD010292-bbs2-0113" title="RahmadiM , NaritaM , YamashitaA , ImaiS , KuzumakiN , SuzukiT . Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran. Synapse2011;65:652-7.">Rahmadi 2011</a>) and insomnia as an adverse event was more frequently reported by participants with SNRIs than with placebo in this review. Therefore it might be possible that a substantial improvement of fibromyalgia pain by duloxetine and milnacipran is not associated with a substantial improvement in other key symptom domains of fibromyalgia in some people. </p> </section> <section id="CD010292-sec-0158"> <h3 class="title" id="CD010292-sec-0158">Agreements and disagreements with other studies or reviews</h3> <p>We cannot share the conclusion of some reviews that the efficacy of duloxetine and milnacipran in the management of fibromyalgia has been proven (<a href="./references#CD010292-bbs2-0046" title="ArnoldLM , ClauwDJ , WohlreichMM , WangF , AhlJ , Gaynor PJ et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(5):237-4.">Arnold 2010c</a>; <a href="./references#CD010292-bbs2-0089" title="KyleJA , DuganBD , TestermanKK . Milnacipran for treatment of fibromyalgia. Annals of Pharmacotherapy2010;44(9):1422-9.">Kyle 2010</a>; <a href="./references#CD010292-bbs2-0110" title="OrmsethMJ , EylerAE , HammondsCL , BoomershineCS . Milnacipran for the management of fibromyalgia syndrome. Journal of Pain Research2010;3:15-24.">Ormseth 2010</a>; <a href="./references#CD010292-bbs2-0121" title="UrsiniF , PipicelliG , GrembialeRD . Efficacy and safety of duloxetine in fibromyalgia. Clinical Therapeutics2010;161(4):391-5.">Ursini 2010</a>). Neither drug has a benefit on all key symptoms of fibromyalgia. Our results are in line with Cochrane Pain and Palliative and Supportive Care reviews that analyse drugs for fibromyalgia separately. <a href="./references#CD010292-bbs2-0060" title="CordingM , DerryS , PhillipsT , MooreRA , WiffenPJ . Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD008244]">Cording 2015</a> included six studies with 4238 participants in total in a review of milnacipran in fibromyalgia. The review authors concluded that milnacipran 100 mg or 200 mg per day was effective only for a minority of people in the treatment of pain due to fibromyalgia, providing moderate levels of pain relief (at least 30%) to about 40% of participants, compared with about 30% with placebo. The use of last observation carried forward imputation may overestimate the efficacy of milnacipran. Using stricter criteria for 'responder' and a more conservative method of analysis gave lower response rates (about 26% with milnacipran versus 17% with placebo). Withdrawals for any reason were more common with milnacipran than placebo, and more common with 200 mg (NNTH 9) than 100 mg (NNTH 23), compared with placebo. This was largely driven by adverse event withdrawals, where the NNTH compared with placebo was 14 for 100 mg and 7 for 200 mg (<a href="./references#CD010292-bbs2-0060" title="CordingM , DerryS , PhillipsT , MooreRA , WiffenPJ . Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD008244]">Cording 2015</a>). Lunn and co‐authors included six studies involving 2249 participants with fibromyalgia. Duloxetine at 60 mg daily was effective for fibromyalgia over 12 weeks (RR for ≥ 50% reduction in pain 1.57, 95% CI 1.20 to 2.06; NNTB 8, 95% CI 4 to 21) and over 28 weeks (RR 1.58, 95% CI 1.10 to 2.27). Adverse events were common in both treatment and placebo arms but more common in the treatment arm, with a dose‐dependent effect. Most adverse events were minor (<a href="./references#CD010292-bbs2-0095" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 1, Issue 2014. [DOI: 10.1002/14651858.CD007115]">Lunn 2014</a>). Our results do confirm the conclusions of the aforementioned reviews, that tolerability and safety of both drugs is limited, because a substantial number of participants dropped out of trials due to adverse events. The most frequent adverse events in both drugs were nausea, dry mouth, headache, constipation and hyperhidrosis (increased perspiration) (<a href="./references#CD010292-bbs2-0060" title="CordingM , DerryS , PhillipsT , MooreRA , WiffenPJ . Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD008244]">Cording 2015</a>). The lack of difference in serious adverse events between SNRI and placebo demonstrated that most adverse effects were considered minor. </p> <p>We cannot share the conclusion of a systematic review that venlafaxine (which is metabolized to desvenlafaxine) is "at least modestly effective in treating fibromyalgia" (<a href="./references#CD010292-bbs2-0122" title="VanderWeideLA , SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of Clinical Pharmacy and Therapeutics2015;40:1-6.">VanderWeide 2015</a>). <a href="./references#CD010292-bbs2-0122" title="VanderWeideLA , SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of Clinical Pharmacy and Therapeutics2015;40:1-6.">VanderWeide 2015</a> included one RCT with venlafaxine. There was no difference between venlafaxine and placebo in ITT analysis in pain reduction at the end of treatment (six weeks) (<a href="./references#CD010292-bbs2-0040" title="VanderWeide, SmithSM , TrinkleyKE . A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics2015;40:1-6. ZiljstraTK , BarendregtPJ , Van der LaarMAF . Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism2002;52:S105. ">Ziljstra 2002</a>). We found no differences between desvenlafaxine and placebo in pain reduction in one trial (<a href="./references#CD010292-bbs2-0015" title="NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&amp;Search=Search First posted: June 13, 2008. ">NCT00697787</a>). </p> <p>The results of our subgroup comparisons of duloxetine and milnacipran are in line with the ones of network meta‐analyses that did not find significant differences between the two drugs in pain reduction and tolerability (<a href="./references#CD010292-bbs2-0092" title="LeeYH , SongGG . Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatology International2016;36:663-72.">Lee 2016</a>; <a href="./references#CD010292-bbs2-0109" title="NüeschE , HäuserW , BernardyK , BarthJ , JüniP . Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Annals of Rheumatic Diseases2013;72:955-62.">Nüesch 2013</a>). However, these network meta‐analyses did not test for some other outcomes relevant for people with fibromyalgia. We found that duloxetine was superior to milnacipran in reducing sleep problems, depression, disability, cognitive disturbances and improving global well‐being. </p> <p>Routine clinical care data call into question the long‐term effectiveness or tolerability, or both, of duloxetine and milnacipran in the majority of people with fibromyalgia. A longitudinal study in people with fibromyalgia of the National Data Bank of Rheumatic Diseases found that pain scores were reduced significantly, but not clinically relevantly by 0.17 (95 % CI 0.03 to 0.30) units on an 11‐point scale following the start of therapy with duloxetine or milnacipran or pregabalin. There was no significant improvement in fatigue or functional status with these drugs (<a href="./references#CD010292-bbs2-0130" title="WolfeF , WalittBT , KatzRS , LeeYC , MichaudKD , HäuserW . Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain2013;17:581-6.">Wolfe 2013b</a>). In a retrospective analysis using a US claims database to identify adults with a first diagnosis of fibromyalgia between 2009 and 2011, the discontinuation rates were 52% for duloxetine and 72% for milnacipran after 12 months (<a href="./references#CD010292-bbs2-0094" title="LiuY , QianC , YangM . Treatment patterns associated with ACR-recommended medications in the management of fibromyalgia in the United States. Journal of Managed Care &amp; Specialty Pharmacy2013;22:263-71.">Liu 2016</a>). The one‐year discontinuation rate of SSRI/SNRI antidepressants including duloxetine and milnacipran was 74% in patients of a large Israeli Health Maintenance Organisation (<a href="./references#CD010292-bbs2-0050" title="Ben-Ami ShorD , WeitzmanD , DahanS , GendelmanO , Bar-OnY , Amital D et al. Adherence and persistence with drug therapy among fibromyalgia patients: data from a large health maintenance organization. Journal of Rheumatology2017;10:1499-1506.">Ben‐Ami 2017</a>). </p> <p>Considering the current differences in regulatory approval regarding the use of duloxetine and milnacipran in fibromyalgia in the USA and Japan versus Europe, it seems relevant to comment on whether our data support either of these positions. There was one European study each with duloxetine (<a href="./references#CD010292-bbs2-0008" title="ChappellAS , BradleyLA , WiltseC , DetkeMJ , D'SouzaDN , SpaethM . A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine2009;30(1):91-102. ">Chappell 2009a</a>) and milnacipran (<a href="./references#CD010292-bbs2-0007" title="BrancoJC , ZachrissonO , PerrotS , MainguyY , Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology2010;37(4):851-9. ">Branco 2010</a>). According to EMA analysis, duloxetine and milnacipran did not meet the primary endpoint of the study, namely the superiority over placebo in the reduction of mean pain intensity (<a href="./references#CD010292-bbs2-0067" title="European Medicines Agency. Refusal assessment report for Cymbalta. International non-proprietary name/common name: (duloxetine hydrochloride) Procedure No. EMEA/H/C/572/II/26. Available at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000572/WC500076168.pdf Accessed 30 July 2009.">EMA 2008</a>; <a href="./references#CD010292-bbs2-0068" title="European Medicines Agency. Refusal assessment report for milnacipran Pierre Fabre Medicament. International non-proprietary name: milnacipran. Procedure No. EMEA/H/C/001034. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001034/WC500089828.pdf Accessed 30 July 30 2010.">EMA 2010</a>). Our analyses demonstrated a superiority of duloxetine and milnacipran respectively in pain relief of 50% or more. It is our view that the trial data show that the benefits of duloxetine and milnacipran (NNTB 11 for an incremental 50% pain reduction) are nearly counterbalanced by the risk of side effects (NNTH 14 for an incremental dropout rate due to adverse events). The data do not provide clear support for either of the regulatory positions over the other. Thus, our review cannot provide support for any of these regulatory positions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010292-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010292-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010292-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010292-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 1: Self‐reported pain relief of 50% or greater" data-id="CD010292-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 1: Self‐reported pain relief of 50% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 2: PGIC much or very much improved" data-id="CD010292-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 2: PGIC much or very much improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 3: Withdrawal due to adverse events" data-id="CD010292-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 3: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 4: Serious adverse events" data-id="CD010292-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 5: Self‐reported fatigue" data-id="CD010292-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 5: Self‐reported fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 6: Self‐reported sleep problems" data-id="CD010292-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 6: Self‐reported sleep problems </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 7: Self‐reported health‐related quality of life" data-id="CD010292-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 7: Self‐reported health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 8: Self‐reported pain relief of 30% or greater" data-id="CD010292-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 8: Self‐reported pain relief of 30% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 9: Self‐reported mean pain intensity" data-id="CD010292-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 9: Self‐reported mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 10: Self‐reported depression" data-id="CD010292-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 10: Self‐reported depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 11: Self‐reported anxiety" data-id="CD010292-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 11: Self‐reported anxiety </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 12: Self‐reported disability" data-id="CD010292-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 12: Self‐reported disability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 13: Self‐reported cognitive disturbances" data-id="CD010292-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 13: Self‐reported cognitive disturbances </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 14: Tenderness" data-id="CD010292-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 14: Tenderness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 15: Withdrawal due to lack of efficacy" data-id="CD010292-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 15: Withdrawal due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 16: Nausea" data-id="CD010292-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 16: Nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 17: Somnolence" data-id="CD010292-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 17: Somnolence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010292-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/urn:x-wiley:14651858:media:CD010292:CD010292-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 18: Insomnia" data-id="CD010292-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_t/tCD010292-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: SNRIs versus placebo in parallel and cross‐over design trials, Outcome 18: Insomnia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/media/CDSR/CD010292/image_n/nCD010292-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010292-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fibromyalgia </p> <p><b>Settings:</b> study centers in North, Central and South America, Asia and Europe </p> <p><b>Intervention:</b> serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with intervention</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect</b> </p> <p><b>SMD or risk difference</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported pain relief of 50% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b> </p> <p><b>(282 to 344)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.09 (0.07 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6918 (15 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (95% CI 9 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression to be much or very much improved (PGIC)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b> </p> <p><b>(459 to 573)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.19 (0.12 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2918 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 5 (95% CI 4 to 8)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported fatigue (20‐100 scale)</b> </p> <p>Higher scores indicate higher fatigue problem levels</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean fatigue<br/>score was 2.6 points<br/>lower (1.0 to<br/>5.0 points lower) based on a 20‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 69.4 (SD 12.3)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.18 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6168 (12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 18 (95% CI 12 to 29)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported sleep problems</b> </p> <p><b>(0‐100 scale)</b> </p> <p>Higher scores indicate higher sleep problem levels</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean sleep problems<br/>score was 1.2 points<br/>lower (0.2 higher to<br/>5.5 points lower) based on a 0‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 68.0 (23.8)<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.07 (‐0.15 to 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4547 (8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB not calculated due to lack of statistically significant difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported health‐related quality of life (0‐100 scale)</b> </p> <p>Higher scores indicate higher burden of disease (lower quality of life)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean health‐related quality of life problems score was 3.9 points lower (2.3 to<br/>5.3 points lower) based on a<br/>0‐100 scale </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline mean score 57.9 (SD<br/>14.1)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.20 (‐0.25 to ‐0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6861 (14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (95% CI 8 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tolerability (withdrawal due to adverse events)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> <p><b>(172 to 210)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.07 (0.04 to 0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7029 (15 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 14 (95% CI 10 to 25)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (serious adverse events)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p><b>(16 to 20)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD ‐0.00 (‐0.01 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6732 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>1,2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not calculated due to lack of statistically significant difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : Confidence interval; <b>FIQ</b> : Fibromyalgia Impact Questionnaire; <b>MFI</b> : Multidimensional Fatigue Inventory; <b>MOS‐Sleep problem index</b> : Medical Outcome Study ‐ sleep problem index; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harm; <b>NRS</b> : numerical rating scale; <b>RD</b> : risk difference; <b>SMD</b> : standardized mean difference; <b>VAS</b>: visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once: indirectness: participants with major medical diseases and mental disorders except major depression excluded in &gt; 50% of studies<br/><sup>2</sup>Downgraded once: publication bias<br/><sup>3</sup><a href="./references#CD010292-bbs2-0009" title="ClauwDJ , MeaseP , PalmerRH , GendreauRM , WangY . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics2008;30(11):1988-2004. ">Clauw 2008</a>: N = 401 participants; MFI NRS 20‐100 scale<br/><sup>4</sup><a href="./references#CD010292-bbs2-0013" title="MeasePJ , ClauwDJ , GendreauRM , RaoSG , KranzlerJ , Chen W et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology2009;36(2):398-409. ">Mease 2009b</a>: N = 223 participants; MOS Sleep problem index NRS 0‐100 scale<br/><sup>5</sup><a href="./references#CD010292-bbs2-0004" title="ArnoldLM , GendreauRM , PalmerRH , GendreauJF , WangY . Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism2010;62(9):2745-56. ">Arnold 2010b</a>; N = 509 participants; FIQ VAS 0‐80 scale<br/><sup>6</sup>Downgraded once: imprecision due to low event rate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010292-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis. Efficacy and safety of SNRIs in studies with North American and European participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number</b> </p> <p><b>of</b> </p> <p><b>participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect size</b> </p> <p><b>RD (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test for</b> </p> <p><b>overall</b> </p> <p><b>effect</b> </p> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Heterogeneity</b> </p> <p><b>I²</b> (<b>%</b>) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test of interaction:</b> </p> <p><b>effect estimate and P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported pain relief 50% or greater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Z = 0.78; P = 0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only North American participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3935 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.08 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only European participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.01 to 0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Z = 1.14; P = 0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only North American participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3935 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (0.04 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only European participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>960 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.08 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>RD</b> : risk difference; <b>SNRIs</b>: serotonin and noradrenaline reuptake inhibitors </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Subgroup analysis. Efficacy and safety of SNRIs in studies with North American and European participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/full#CD010292-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010292-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SNRIs versus placebo in parallel and cross‐over design trials</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Self‐reported pain relief of 50% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.07, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.06, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 PGIC much or very much improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.27, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.11, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.04, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.09, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.01, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Self‐reported fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.18, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.21, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Milnacpran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Self‐reported sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.15, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.31, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Self‐reported health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.25, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.30, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.25, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Self‐reported pain relief of 30% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.07, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Self‐reported mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.27, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.27, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.35, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Milncipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.26, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Self‐reported depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.21, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.34, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.17, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Self‐reported anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.21, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.17, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.36, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Self‐reported disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.26, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.37, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.22, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Self‐reported cognitive disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.21, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.38, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.18, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Tenderness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.33, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.35, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.31, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Withdrawal due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.04, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.02, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.04, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.14, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.10, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.15, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.12, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.17, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Desvenlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.18, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Milnacipran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SNRIs versus placebo in parallel and cross‐over design trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010292.pub2/references#CD010292-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010292.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010292-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010292-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010292-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010292-note-0008">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD010292-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010292-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010292\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010292\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010292\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010292\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010292\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010292.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010292.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010292.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010292.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010292.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718787727"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010292.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718787731"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010292.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd8dc4a1e935f',t:'MTc0MDcxODc4OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 